

$PDGFR\alpha$ -induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms

Jean-Marie Jacob, Selene Di Carlo, Igor Stzepourginski, Anthony Lepelletier, Papa Diogop Ndiaye, Hugo Varet, Rachel Legendre, Etienne Kornobis, Adam Benabid, Giulia Nigro, et al.

▶ To cite this version:

Jean-Marie Jacob, Selene Di Carlo, Igor Stzepourginski, Anthony Lepelletier, Papa Diogop Ndiaye, et al.. PDGFR α -induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms. Cell Stem Cell, 2022, 29 (5), pp.856 - 868.e5. 10.1016/j.stem.2022.04.005. pasteur-03662197

HAL Id: pasteur-03662197 https://pasteur.hal.science/pasteur-03662197

Submitted on 9 May 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Cell Stem Cell

PDGFR α -induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms

Graphical abstract



Authors

Jean-Marie Jacob, Selene E. Di Carlo, Igor Stzepourginski, ..., Adam Benabid, Giulia Nigro, Lucie Peduto

Correspondence

lucie.peduto@pasteur.fr

In brief

After birth, the intestine undergoes villus and vascular remodeling to fulfill nutrient requirement and enhance intestinal barrier function. Peduto and colleagues show that postnatal PDGFRa-dependent intestinal stromal maturation is required to restrain stemness and promote epithelial differentiation and immunorequlation. Failure of stromal maturation leads to decreased postnatal growth and dysregulated intestinal inflammatory and repair responses.

Highlights

- Intestinal LTBR⁺PDGFR^{dHigh} stromal lineage develops in the first weeks after birth
- The LTBR stromal lineage restrains stemness and promotes intestinal maturation in vivo
- PDGFRα orchestrates spatial and molecular specificities of intestinal stromal niches
- Development of the LTBR lineage is required for postnatal growth and repair responses

Jacob et al., 2022, Cell Stem Cell 29, 856-868 May 5, 2022 © 2022 The Authors. Published by Elsevier Inc. https://doi.org/10.1016/j.stem.2022.04.005



CellPress OPEN ACCESS

Cell Stem Cell

Article

PDGFRα-induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms

Jean-Marie Jacob,¹ Selene E. Di Carlo,^{1,5} Igor Stzepourginski,^{1,4,5} Anthony Lepelletier,¹ Papa Diogop Ndiaye,¹ Hugo Varet,^{2,3} Rachel Legendre,^{2,3} Etienne Kornobis,^{2,3} Adam Benabid,¹ Giulia Nigro,¹ and Lucie Peduto^{1,6,*} ¹Stroma, Inflammation & Tissue Repair Unit, Institut Pasteur, Université Paris Cité, INSERM U1224, Paris, France

²Transcriptome and Epigenome Platform-Biomics Pole, Institut Pasteur, Université Paris Cité, Paris, France

³Bioinformatics and Biostatistics Hub, Institut Pasteur, Université Paris Cité, Paris, France

⁴Present address: Eligo Biosciences, Paris, France

⁵These authors contributed equally

⁶Lead contact

*Correspondence: lucie.peduto@pasteur.fr https://doi.org/10.1016/j.stem.2022.04.005

SUMMARY

After birth, the intestine undergoes major changes to shift from an immature proliferative state to a functional intestinal barrier. By combining inducible lineage tracing and transcriptomics in mouse models, we identify a prodifferentiation PDGFR α^{High} intestinal stromal lineage originating from postnatal LT β R⁺ perivascular stromal progenitors. The genetic blockage of this lineage increased the intestinal stem cell pool while decreasing epithelial and immune maturation at weaning age, leading to reduced postnatal growth and dysregulated repair responses. Ablating PDGFR α in the LTBR stromal lineage demonstrates that PDGFR α has a major impact on the lineage fate and function, inducing a transcriptomic switch from prostemness genes, such as *Rspo3* and *Grem1*, to prodifferentiation factors, including BMPs, retinoic acid, and laminins, and on spatial organization within the crypt-villus and repair responses. Our results show that the PDGFR α -induced transcriptomic switch in intestinal stromal cells is required in the first weeks after birth to coordinate postnatal intestinal maturation and function.

INTRODUCTION

The intestine constitutes a surface barrier between the host and the external environment. The structural and functional maturation of the intestinal barrier is achieved during the first weeks after birth (Chin et al., 2017). This requires restriction of intestinal stem cells (ISCs) to the crypts and progressive maturation of epithelial and immune intestinal components, overall ensuring digestive and defense functions and a balanced immunity. Notably, crypts containing ISCs are formed around 2 weeks after birth. ISCs continuously generate transit-amplifying (TA) cells that proliferate and differentiate into specialized epithelial lineages including absorptive enterocytes, enteroendocrine cells, antimicrobial secreting Paneth cells, and mucus-producing goblet cells, altogether providing a first line of intestinal defense (van der Flier and Clevers, 2009; Bry et al., 1994). Maintenance of intestinal homeostasis requires localized expression of prostemness and prodifferentiation factors. Stromal cells expressing PDGFRa, which are present in embryonic intestine and essential for intestinal morphogenesis (Karlsson et al., 2000), play an essential role in this process. In the adult lamina propria, PDGFRα⁺ stromal cells, partially coexpressing FoxL1 or Gli1, maintain crypts ISCs by secreting prostemness factors such as Wnt ligands, bone morphogenetic proteins (BMPs) antagonists

(Grem1, Grem2), and the ISCs mitogen R-spondins. Ablation of Wnt secretion in PDGFR α^+ , FoxL1⁺, or Gli1⁺ stromal cells, as well as genetic depletion of FoxL1⁺ cells, abrogates ISCs proliferation and induces loss of intestinal crypts (Aoki et al., 2016; Degirmenci et al., 2018; Greicius et al., 2018; Shoshkes-Carmel et al., 2018; Batts et al., 2006; Kosinski et al., 2007). BMPs oppose Wnt signaling and promote epithelial differentiation. BMPs are produced by subepithelial PDGFR α^{Hi} Pdpn^{Hi} stromal cells under control of Hedgehog (Hh) ligands, produced by epithelial cells (Stzepourginski et al., 2017; Kosinski et al., 2010; McCarthy et al., 2020). Pdpn⁺ stromal cells play also an essential role in leucocytes migration, positioning, and function (Stzepourginski et al., 2017; Peduto et al., 2009; Perez-Shibayama et al., 2019), suggesting additional immunoregulatory roles.

Postnatal intestinal development requires immune maturation to adapt to microbial density and complexity, food antigens, and potential enteric pathogens. In the small intestine, these changes include homing and expansion of immune populations including myeloid populations such as CD103⁺CD11b⁺ dendritic cells (DCs) that are essential for neonatal immunity (Lantier et al., 2013). Mostly localized in the intestinal villi, CD103⁺CD11b⁺ DCs migrate to the mesenteric lymph node (mLN) where they promote differentiation of regulatory T cells (Tregs) in presence



of retinoic acid (RA) and TGF- β . Tregs are key to control the differentiation and activity of effector intestinal T helper subsets (Laffont et al., 2010; Persson et al., 2013; Coombes et al., 2007; Iwata et al., 2004).

One major factor regulating the cross talk between Pdpn⁺ stromal cells and immune cells is lymphotoxin beta receptor (LT β R). LT β R is required for the development of lymphoid organs and is expressed by different cell types including stromal progenitors with roles in development and inflammation (Lu and Browning, 2014; Bénézech et al., 2010; Fütterer et al., 1998; Bénézech et al., 2012; Krautler et al., 2012). To investigate in vivo the role of $LT\beta R^+$ stromal cells in the intestine, we generated reporter and inducible lineage tracing models for $LT\beta R^+$ cells. We show that a subset of intestinal PDGFR α^+ stromal progenitors expressing LTBR after birth is required for postnatal intestinal epithelial and immune maturation. We demonstrate that development, maturation, and spatial organization of the LTBR stromal lineage requires PDGFRa, and failure for such postnatal stromal maturation leads to reduced postnatal growth, dysregulated intestinal homeostasis, and enhanced susceptibility to inflammation.

RESULTS

Ltbr-expressing cells generate a subepithelial perivascular Pdpn⁺PDGFR α^+ stromal lineage in the first weeks after birth

To investigate $LT\beta R^+$ stromal progenitors in the intestine, we generated BAC transgenic mice expressing the tetracycline transactivator (tTA) under control of the Ltbr promotor (LTBRtTA mice). By crossing LTBR-tTA mice with tet-regulated Cre (LC1) mice and Rosa26^{floxSTOP-YFP} mice (termed LTBR^{YFP} mice, Figure 1A), we performed lineage tracing of $LT\beta R^+$ cells (in this tet-off system, doxycycline (dox) prevents Cre activation, Figure S1A). In the absence of dox, and consistent with the reported expression of LTBR (Lu and Browning, 2014: Macho-Fernandez et al., 2015), subsets of endothelial, immune, and epithelial cells expressed YFP in the small intestine of adult LTBR^{YFP} mice (Figures S1B and S1C). In addition, we observed around 8% of CD45⁻CD31⁻PDGFRα⁺Pdpn⁺ stromal cells of the small intestine lamina propria expressing YFP (Figure 1B). YFP was not detected in Pdpn⁻ stromal cells (Figure S1E). YFP⁺ stromal cells expressed higher levels of Pdpn and PDGFRa compared with YFP⁻ stromal cells and were wrapped around subepithelial capillaries with multiple elongated processes, closely adjacent to epithelial cells (Figures 1C, 1D, and S1F). YFP⁺ stromal cells were mostly enriched in the villi, at the villus bottom and at the junction of villus crypts (Figures 1C and 2A), whereas only rare cells were found around crypts (Figure S1D). Few YFP⁺ stromal cells were observed in the colon (Figure S1G). The intestine undergoes profound structural and cellular changes in the first weeks after birth (Chin et al., 2017). To investigate when intestinal YFP⁺ stromal cells develop, we performed FACS analysis of stromal cells in the small intestine of newborn, 2-, 4-, and 8-week-old LTBR^{YFP} mice (Figure 1E). Although Pdpn⁺ or PDGFR α^+ stromal cells are present in the intestine at birth (Stzepourginski et al., 2017), we did not detect YFP⁺ stromal cells in newborn LTBR^{YFP} mice (Figures 1E and S1H). YFP⁺ cells strongly expanded between weeks 2 and 4 and then gradually



increased until adult age (Figure 1E, green columns). YFP⁺ stromal population was decreased by the administration of antibiotics, suggesting a role for the microbiota in their development (Figure 1E, blue column). When dox was administrated until week 4, preventing postnatal labeling, only 3% of intestinal stromal cells expressed YFP at 8 weeks (Figure 1E, red column). These results indicate that a major fraction of PDGFR α^+ subepithelial stromal cells generated from LTBR⁺ progenitors develop before weaning age, and low numbers of LTBR⁺ stromal progenitors are still present in adult intestine. To confirm this hypothesis, we generated a direct LTBR^{GFP} reporter model (Figure 1F). Expression pattern of GFP was consistent with reported $LT\beta R$ expression (Lu and Browning, 2014; Macho-Fernandez et al., 2015; Figures S1I–S1K). In the intestinal lamina propria, we detected around 1% of PDGFR α^+ stromal cells expressing GFP close to the intestinal epithelial layer (Figures 1F and 1G), showing that a small fraction of PDGFRa⁺LTBR⁺ stromal progenitors are still present in adult intestine. Analysis of available single-cell datasets of the small intestine confirmed Ltbr expression in PDGFR α^{hi} stromal cells (Figure 1H; McCarthy et al., 2020). In addition to subepithelial stromal cells, we observed GFP expression in intestinal endothelial cells (Figure S1K). To investigate lineage relationships, we performed lineage tracing of vascular endothelial (VE)-cadherin⁺ cells. Consistent with the reported expression of VE-cad by endothelial progenitors and fetal liver hematopoietic progenitors (Kim et al., 2005), a majority of intestinal endothelial cells and a fraction of CD45⁺ cells were fate mapped in this setting (Figures S1L and S1M). However, no stromal cells were fate mapped, confirming that endothelial and mesenchymal lineages in the intestine have a distinct origin. Altogether, these results show that a subset of PDGFR α^+ stromal cells expressing $LT\beta R$ in the first few weeks after birth generate a subepithelial and perivascular Pdpn⁺PDGFR α^{High} lineage within the maturing villi, closely adjacent to capillaries, in a process dependent on the microbiota.

The LT β R stromal lineage has a prodifferentiation gene signature at steady state and after injury

To determine whether PDGFRa⁺YFP⁺ and PDGFRa⁺YFP⁻ stromal cells (Figures 1B and 2A) are transcriptionally different, we performed transcriptome analysis by RNA sequencing (RNAseq) (Figure 2B). Consistent with their subepithelial localization, YFP⁺ stromal cells expressed higher levels, compared with YFP⁻ stromal cells, of genes essential for epithelial cell differentiation, such as DII1, Bmp4, Bmp5, the Hh receptor Ptch1, Hh signaling molecules (Foxf2, Nkx2-3, and Gli1, a transcription factor promoting BMPs expression), and Frzb (a Wnt antagonist), and lower levels of genes involved in the maintenance of the epithelial stem cell niche, such as the BMP antagonists Grem1 and Grem2, Rspo2, Rspo3, Chrdl1, Cd34, and Cd81 (Figure 2B; Kosinski et al., 2007, 2010; McCarthy et al., 2020; Stzepourginski et al., 2017). YFP⁺ stromal cells also overexpressed genes related to RA metabolism (Rdh10, Dhrs4, Aldh1a2, Aldh1a3, Aldha2, and Lrat), which promote intestinal immunity and epithelial differentiation (Oliveira et al., 2018; Lukonin et al., 2020), as well as the chemokines Ccl11 and Cxcl14 (Figure 2B). In line with their perivascular subepithelial localization, YFP⁺ stromal cells expressed higher levels of Pdgfrb and Cspg4, expressed by pericytes (Di Carlo and Peduto, 2018), as well as components





Figure 1. *Ltbr*-expressing cells generate a subepithelial perivascular Pdpn⁺PDGFR α^+ stromal lineage in the first weeks after birth (A) Strategy for inducible lineage tracing of *Ltbr*-expressing cells.

(B) FACS plots of CD45⁻CD31⁻Pdpn⁺PDGFR α^+ stromal cells expressing YFP in the small intestine of LTBR^{YFP} mice. One representative plot of 9 mice from 3 individual experiments is shown.

(C and D) Immunofluorescence analysis of the indicated markers in intestinal sections from LTBR^{YFP} mice. Insets shows high expression of PDGFR_α on YFP⁺ stromal cells (C), wrapped around subepithelial CD31⁺ capillaries (D).

(E) Experimental setup and frequency of YFP⁺ cells among intestinal PDGFR α^+ Pdpn⁺ stromal cells at the indicated time in LTBR^{YFP} mice. Data are represented as mean ± SD (n = 3–9 from independent experiments).

(F) Immunofluorescence analysis of GFP, CD31, and PDGFR α in intestinal sections from LTBR^{GFP} mice.

(G) FACS plot of CD45⁻CD31⁻ stromal cells expressing GFP in the small intestine of LTBR^{GFP} mice or nontransgenic littermate. One representative plot of 3 individual experiments is shown. (H) Expression of *Ltbr* in intestinal PDGFR α^+ stromal cells, analyzed from single-cell dataset (GSE130681) (McCarthy et al., 2020).

In (C), (D), and (F), representative images of 3 independent experiments are shown. *p < 0.05, **p < 0.01, ****p < 0.001, as determined by unpaired Student's t test. ns (not significant). Scale bars, 20 μ m. Dapi stains nuclei.

See also Figure S1.

of the basement membrane including *Col4a1*, *Col4a2*, *lama1*, *lamb1*, *lamc1*, and genes coding for collagen VI (*Col6a1*, *a2*, *a4*, and *a5*), which anchors structures to the surrounding ECM (Groulx et al., 2011; Kuo et al., 1997). Immunofluorescence anal-

ysis confirmed localization of YFP⁺ cells within the CollV⁺ basement membrane (Figure S2A). In contrast, YFP⁻ stromal cells expressed higher level of proinflammatory cytokines and chemokines *II*6, *Ccl2*, *Cxcl1*, *Cxcl2*, and *Cxcl1*0, as well as



Ptch1 Ccl11 Rdh10 Foxf2 Bmp4 Nkx2-3 Aldh2 Aldh1a2 Bmp5 Α в Color Key LTBR^{YFP} mice Bmp5 Aldh1a3 Frzb DII1 Lrat Cxcl14 Gli1 Dhrs4 Grem1 Rspo3 Cell PDGFRα⁺YFP[−] sorting Grem2 Cd81 Cxcl2 Cd34 Chrdl1 PDGFRα⁺YFP⁺ Cxcl10 Ccl2 RNAseq Col4a2 Col6a5 PDGFRα YFP CD31 DAPI Cspg4 Col6a4 Pdgfrb Col1a1 С Indo YFP YFP Sparc Col1a2 Sparcl1 Postn Analysis E0 birth YFP YFP Dox D Е F Pathways YFP+ In 1.5 1 0.5 0 -0.5 -1 Entrational Bmp7 Col6a4 Bmp5 Bmp3 Lrat Lama1 Aldh1a Cell adhesion Angiogenesis Negative regulation of cell proliferation Lamb1 Nkx2-3 Digestive tract development -Retinol metabolic process Aldh1a3 ll6 Has1 Nfkb2 Col1a1 Cxcl10 -log10 (pval) Pathways YFP- Inde Cxcl1 Ccl2 Rela Icam1 Rspo: Postn Response to TNF Wnt signaling pathway ECM organization Response to IL1 Sparci PDGFRα YFP CD31 DAPI Inflammatory response Cxcl12 Cd34 Cd81 YFP-Inde YFP G н I YFP+ Indo vs YFP+ YFP- Indo vs YFP-YFP+ Indo vs YFP 499 783 318 116 ltga2 GO_Cell migration 1111 Cdh6 Ccl2 Ccl7 GO Cell adhesion Vtn Ccl11 Ptgs1 GO_Cell proliferation Tnn ll17ra Cxcl1 Mki67 U Tnfaip3 Mcm5 lfitm1 KEGG ECM-receptor interaction Ccne1 lfitm3 KEGG Cell adhesion molecules KEGG_DNA replication log10 (pval)

Common stromal response to injury

PDGFRa YFP ki67 DAPI

PDGFRα YFP Edu DAPI

Figure 2. The LTBR stromal lineage has a prodifferentiation gene signature at steady state and after injury (A) Immunofluorescence analysis of the indicated markers in intestinal sections from LTBR^{YFP} mice.

(B) Differential gene expression analysis by RNA-seq, and heatmap of selected genes in PDGFR α^+ YFP⁺ and PDGFR α^+ YFP⁻ stromal cells isolated from LTBR^{YFP} mice (n = 4).

(C) Experimental strategy for indomethacin treatment.

(D) Immunofluorescence analysis of the indicated markers in intestinal sections of LTBRYFP mice treated with indomethacin as indicated in (C).

(E and F) Enriched pathways (gene ontology) (E) and heatmap of selected genes (F) in PDGFR α^+ YFP⁺ (YFP^{+Indo}) and PDGFR α^+ YFP⁻ (YFP^{-Indo}) stromal cells isolated from the ulcers of indomethacin-treated LTBR^{YFP} mice (n = 4).

(G) Overlap of upregulated genes (FC > 2) in inflamed YFP^{+ Indo} and YFP^{- Indo} stromal cells, versus their respective population at steady state. Representative genes are shown.



structural and matricellular proteins involved in tissue remodeling and inflammation such as Col1a1, Col1a2, Sparc, Postn, and Has1 (Figure 2B). To investigate the fate of the postnatal LTBR⁺ stromal lineage during injury, we injected indomethacin, which induces intestinal ulcers (Sigthorsson et al., 2002), in LTBR^{YFP} mice (Figure 2C). Of note, we added dox from the time of injury to prevent labeling of cells that might upregulate LTBR after injury. We observed that YFP⁺ cells massively expanded in the ulcer's, mostly in the upper part of the lamina propria, and were still loosely connected to blood vessels, surrounded by PDGFR α^+ stromal cells not derived from LTBR lineage (YFP⁻) (Figure 2D). Expansion of YFP⁺ cells was specific to injured regions and was not observed in noninjured zones of indomethacin-treated mice (Figure S2B). Differential expression analysis of PDGFR α^+ YFP⁺ and PDGFR α^+ YFP⁻ stromal cells isolated from ulcers indicated that YFP+ and YFP- populations maintain a distinct gene signature after injury. Accordingly, injury-induced YFP⁺ cells (YFP^{+ Indo}) were enriched in GO terms related to cell adhesion, angiogenesis, basement membrane matrix proteins, prodifferentiation factors, and genes related to RA synthesis (Figures 2E and 2F). In contrast, YFP⁻ cells (YFP^{- Indo}) were enriched in genes promoting Wnt signaling, proinflammatory cytokines, responses to TNF-a and IL1, leukocyte chemoattractants such as Ccl2 and Ccl7, and matrix proteins with roles in fibrosis and inflammation such as Col1a1, Postn, Sparc, and Has1 (Jiang et al., 2007; Ng et al., 2013; Koh et al., 2016; Figures 2E and 2F). Although not unique to a stromal subset, YFP⁻ expressed *ll1r1* (Figure S2C), involved in Rspo3 mediated stromal coordination of intestinal repair after dextran sodium sulfate (DSS) (Cox et al., 2021). We further investigated how gene expression change in each lineage in response to injury. We observed that although YFP⁻ cells overall express higher levels of proinflammatory molecules compared with YFP⁺ cells, both injury-activated YFP⁺ PDGFR α^+ and YFP⁻ PDGFR α^+ stromal lineages upregulated cytokines, chemokines, and IFN-induced genes including //6, //11, Cxc/1, Cc/7, and /fitm3 compared with homeostasis, suggesting a common stromal response related to innate immunity (Figure 2G). In addition, injury-activated YFP⁺ cells specifically upregulated genes regulating cell matrix adhesion, cell migration, and proliferation (Figures 2G and 2H) while downregulating genes involved in Hh signaling such as Gli1, compared with YFP⁺ cells at steady state (Figure S2D). In line with this observation, injury-activated YFP+ cells rapidly detached from the damaged villus epithelium, the major producer of Hh ligands, accumulated at the bottom of the villus and massively proliferated and migrated within the wound in the first few days after injury (Figure 2I). Altogether, these results show that the postnatal YFP⁺PDGFR α^+ stromal lineage is enriched in factors essential for epithelial differentiation/ integrity and immunoregulation, whereas YFP⁻PDGFRa⁺ stromal cells express genes involved in the maintenance of the ISCs niche, matrix remodeling, and inflammation. After injury, YFP⁺PDGFRa⁺ cells, which are strategically localized in the villi to sense damage, rapidly proliferate and migrate within the wound.

Cell Stem Cell Article

Conditional ablation of $PDGFR\alpha$ in the LTBR lineage restrains postnatal intestinal maturation

Our results indicate that the LTBR lineage develops in the first few weeks after birth, a key period for intestinal maturation (Noah et al., 2011) and expresses high levels of PDGFRa (Figures 1C and 1H), which plays fundamental roles in cell growth and differentiation (Hoch and Soriano, 2003; Olson and Soriano, 2009). To investigate the role of PDGFR α in the LTBR lineage, we crossed LTBR-tTA mice to tet-regulated Cre (LC1) mice and PDGFRa^{fl/fl} mice (LTBR^{△PDGFRa} mice; Figure 3A), and removed dox at birth to ablate postnatal PDGFR α in YFP⁺ cells (Figure 3B). We observed that LTBR^{APDGFRa} pups gained significantly less weight starting from week 2 compared with their WT littermates (Figure 3C), which is when intestinal YFP⁺ stromal cells develop (Figure 1E). In the intestine of LTBR^{△PDGFRa} mice, we did not observe major differences in the intestinal length, overall structure, and gut-associated lymphoid tissues compared with 4-week-old littermates (Figures 3D, S3A, and S3B). In contrast, we observed a significant increase in Olfm4⁺ cells, a marker for ISCs (Schuijers et al., 2014; Figure S3C), as well as in Lgr5⁺ ISCs (Figure S3D), and EdU⁺ proliferating epithelial cells in LTBR $^{\triangle PDGFRa}$ mice compared with WT littermates, although goblet cells were decreased (Figure 3D). No differences were detected in Paneth cells and Tuft cells (Figures 3D and S3E). Consistent with an increase in the stem cells pool, epithelial cells isolated from LTBR^{△PDGFRa} mice had increased expression of transcripts coding for the ISCs markers Olfm4, Lgr5 (Hadis et al., 2011; van der Flier et al., 2009; Barker et al., 2007), and EphB3, a target of Wnt signaling (Figure 3E; Qi et al., 2017), compared with epithelial cells isolated from the intestine of WT littermate mice. In addition, epithelial cells isolated from LTBR<sup>
DGFRa</sup> mice showed decreased expressions of Klf4 and Muc2, expressed by goblet cells, of Sucrase isomaltase (Sis), expressed in mature enterocytes, as well as Tff3 (mainly produced by goblet cells) and Tjp2 (ZO-2) that have essential roles in maintenance of epithelial tight junctions (Figure 3E). Of note. Sis is essential for digestion of dietary carbohydrates (Muncan et al., 2011), suggesting that a defect in enterocyte maturation might be involved in the lower weight of LTBR APDGFRa mice. In line with the proliferative phenotype, we observed that stromal cells isolated from LTBR $^{{\scriptscriptstyle \bigtriangleup}\,{\rm PDGFRa}}$ mice expressed lower levels of BMPs and Wnt antagonists and higher levels of prostemness signals such as Grem2 and Chrdl1 (Figure S3F). As postnatal intestinal maturation is concomitant to immune recruitment, we analyzed the frequency of lamina propria immune cells in LTBR^{△PDGFRa} mice. We did not observe significant differences in B cells, T helper subsets, CD8⁺ T cells, ILCs, or major populations of myeloid cells in LTBR^{△PDGFRa} mice (Figure S3G). In contrast, we observed a significant decrease in intestinal CD103⁺CD11b⁺ DCs (Figure 3F), which expressed RA, a major factor regulating intestinal Tregs homeostasis (Tanoue et al., 2016; Figure S4A). Intestinal CD103⁺CD11b⁺ DCs migrate to the mLN and induce differentiation of Tregs (Coombes et al., 2007; Ruane and Lavelle, 2011; Schulz et al., 2009). Consistent

⁽H) Enriched pathways in YFP^{+Indo} versus YFP⁺ stromal cells excluding overlap genes.

⁽I) Immunofluorescence analysis of the indicated markers in intestinal sections of LTBR^{YFP} mice treated with indomethacin for 1 day (left) or 4 days (right). In (A), (D), and (I), one representative image from 3 individual experiments is shown. U, Ulcer; C, Crypt; V, Villus. Scale bars, 50 µm. See also Figure S2.





Figure 3. Conditional ablation of PDGFRa in the LTBR lineage restrains postnatal intestinal maturation

(A) Strategy for conditional ablation of PDGFR α in the LTBR lineage.

(B) Experimental setup in (C)-(H).

(c) Body weight of LTBR \triangle^{PDGFRa} mice and WT littermates at the indicated age after birth. n = 7–10 from at least 3 independent experiments. The line connects the mean ± SD of each time point.

(D) H&E staining and immunofluorescence analysis of the indicated markers on intestinal sections. N = 6-9 mice from 2 to 5 independent experiments.

(E) Expression of the indicated genes, measured by qRT-PCR, on the epithelial fraction. n = 8-10 from 3 independent experiments.

(F) Frequency (left) and cell number (right) of intestinal CD103⁺CD11b⁺ DCs, measured by FACS. n = 5–7 mice from 2 independent experiments, representative of 3.

(G and H) Frequency of CD103⁺CD11b⁺ DCs (G) and RORgt⁺Foxp3⁺ T cells (H) in the mesenteric lymph node (mLN). n = 4-5 mice from 2 independent experiments (G) and n = 10-13 from 4 independent experiments (H).

(I) CD103⁺CD11b⁺ BM derived DCs, measured by FACS, cultivated with Pdpn⁺ stromal cells isolated by FACS from the small intestine of 4-week-old LTBR^{Δ PDGFRa} mice or WT littermates. n = 8–11 from 4 independent experiments.

In (D)–(I), data are represented as mean ± SD. ns (not significant). *p < 0.05, **p < 0.01, *** < 0.001, **** p < 0.001 as determined by unpaired Student's t test. Scale bars, 50 µm.

See also Figures S3 and S4.

with a decrease of intestinal CD103⁺CD11b⁺ DCs, we observed a decrease of CD103⁺CD11b⁺ DCs in the mLN of LTBR^{\triangle PDGFRa</sub> mice (Figure 3G), as well as of RORgt⁺FoxP3⁺ Tregs induced in the mLN (Figure 3H) and a trend of decrease of intestinal RORgt⁺FoxP3⁺ Tregs (data not shown). We observed that a majority of intestinal CD11c⁺CD103⁺ DCs were closely adjacent to YFP⁺ cells (Figures S4B and S4C), suggesting a cross talk stroma-DCs. Consistent with this hypothesis, Pdpn⁺ stromal cells isolated from LTBR^{\triangle PDGFRa} mice were less efficient than WT Pdpn⁺ stroma to maintain CD103⁺CD11b⁺ BM-DCs *in vitro* (Figure 3I). Altogether, these data show that PDGFRa expression in the LTBR stromal lineage is required for postnatal mice growth and intestinal epithelial and immune maturation.}

LTBR^{△PDGFRa} mice display dysregulated responses to intestinal injury

Our results show that LTBR^{\triangle PDGFRa} mice have dysregulated intestinal epithelial and immune postnatal maturation. To determine whether such dysregulation has an impact on inflammation, we treated 4-week-old LTBR^{\triangle PDGFRa} mice and littermate WT mice with DSS (Figure 4A). We did not observe major structural changes in the small intestine of DSS-treated LTBR^{\triangle PDGFRa} mice and littermate mice, consistent with previous reports showing that DSS-induced ileal inflammation has minor epithelial damage (Sartor, 1997). Nevertheless, we detected higher expression of *Pdgfa* in the small intestine of DSS-treated LTBR^{\triangle PDGFRa} mice and littermates compared with nontreated





Figure 4. LTBR^{APDGFRa} mice display dysregulated response to intestinal injury

(A) Experimental strategy for DSS treatment in (B)-(D).

(B) H&E coloration of intestinal sections of DSS-treated LTBR^{ΔPDGFRa} mice and WT littermates. Arrows indicates highly infiltrated zones. Scale bars, 50 μm.
(C) Frequency of the indicated immune populations in the small intestine of DSS-treated LTBR^{ΔPDGFRa} mice and WT littermates. n = 4–9 from 2 independent experiments.

(D) Expression of the indicated transcripts, as measured by qRT-PCR, in the small intestine of DSS-treated LTBR^{ΔPDGFRa} mice and WT littermates. n = 13–17 from 3 independent experiments.

(E) Experimental strategy for indomethacin treatment in (F)-(H).

(F and G) Images of indomethacin induced intestinal ulcers (stained with Evan's Blue, black arrows in F), and measure of ulcers area (G) in LTBR^{\triangle PDGFRa} mice and WT littermates. Representative images from 3 independent experiments are shown (n = 7–8).

(H) H&E coloration (left, arrowheads indicate epithelial coverage) and quantification of ulcer's coverage by epithelial cells (right). A minimum of 20 ulcers were analyzed from 14 mice from 2 independent experiments, and one representative image is shown. Scale bars, 100 µm.

In (C), (D), and (G), data are represented as mean ± SD. *p < 0.05, **p < 0.01 as determined by unpaired Student's t test. EB: Evan's Blue. See also Figure S4.

mice, suggesting a role for PDGF in inflammation (Figure S4D). We further observed intestinal length shortening (Figure S4E) and increased leucocyte infiltration and thickness of the smooth muscle layer in the small intestine of DSS-treated LTBR $^{\triangle PDGFRa}$ mice (Figure 4B), consistent with increased inflammation. Accordingly, the frequency of neutrophils, Ly6C^{High} monocytes, and inflammatory macrophages in the small intestine of

LTBR^{\triangle PDGFRa} mice was increased following DSS (Figure 4C), as well as expression of the proinflammatory cytokines *II1b* and *II18* (Figure 4D), but not at steady state (Figure S4F). Tregs were not significantly impacted (Figure S4G). As we did not observe damage to the epithelium in DSS-induced ileitis, we injected indomethacin in 4-week-old LTBR^{\triangle PDGFRa} mice and WT littermates (Figure 4E) to further investigate epithelial repair.





Figure 5. PDGFRa induces a major transcriptomic switch in the LTBR stromal lineage

(A) Strategy for the generation of LTBR^{△PDGFRa/YFP} mice.

(B) Experimental setup in (C) and (D).

(C) FACS plot and percentage of CD45⁻CD31⁻ stromal cells expressing YFP in the small intestine of the indicated mice treated as in (B); n = 10 from 4 independent experiments.

(D) Immunofluorescence analysis of the indicated markers in intestinal sections from LTBR^{APDGFRa/YFP} mice (left) and percentage of YFP⁺PDGFRa^{/High} stromal cells (arrow) and YFP⁺PDGFRa⁻ (arrowhead) in the indicated mice (right). Quantification was done on 30 images from 4 independent experiments. (E) Immunofluorescence analysis of the indicated markers in intestinal sections from 4-week-old LTBR^{ΔPDGFRa/YFP} mice.

(F) Mean fluorescence intensity (MFI) of PDGFRa expression in YFP⁺ stromal cells from LTBR^{APDGFRa/YFP} mice. One representative plot is shown (n = 6–12). (G) RNA-seq analysis and heatmap of selected genes differentially expressed in YFP⁺PDGFRa⁺ stromal cells versus YFP⁺PDGFRa⁻ stromal cells isolated from LTBR^{\triangle PDGFRa/YFP} mice, n = 4 mice.

(H) Immunofluorescence analysis of the indicated markers in intestinal sections of 4-week-old LTBR^{APDGFRa/YFP} mice treated with indomethacin for 4 days. (I) Expression of Pdgfa measured by qRT-PCR in the indicated populations isolated by FACS from the small intestine of WT mice. n = 4-6 from 2 independent experiments.



We observed decreased ulceration surface in the small intestine of LTBR^{\triangle PDGFRa} mice compared with WT littermate mice (Figures 4F and 4G). Histological analysis indicated that the majority of ulcers lacked epithelial coverage in WT littermate mice, although similar size ulcers in LTBR^{\triangle PDGFRa} mice were mostly covered by epithelial cells (Figure 4H, red arrowheads), suggesting improved regeneration. Overall, these results show that expression of PDGFRa in the LTBR stromal lineage is required to regulate postnatal repair and inflammatory intestinal responses.

PDGFR α induces a major transcriptomic switch in the LTBR stromal lineage

To investigate the underlying mechanism, we engineered a genetic model to trace YFP⁺ cells in postnatal LTBR^{APDGFRa} mice. To that aim, we crossed LTBR^{△PDGFRa} mice to Rosa26^{floxSTO-} PYFP reporter mice (LTBR^{△PDGFRa/YFP} mice; Figure 5A), removed dox at birth, and analyzed the small intestine of 4-week-old LTBR^{△PDGFRa/YFP} mice (Figure 5B). Compared with LTBR^{YFP} mice, which have WT expression of PDGFRa, YFP⁺ stromal population in LTBR^{△PDGFRa/YFP} mice was decreased by 50% (Figure 5C), showing that the deletion of PDGFR α from YFP⁺ stromal cells regulate their development or survival. Consistent with specific expression of PDGFRa in stromal cells (Figure S5A), YFP⁺ endothelial and YFP⁺ immune cells were not affected (Figure S5B). Less than 5% of YFP⁺ cells still present in the small intestine of LTBR^{APDGFRa/YFP} mice expressed high levels of PDGFRa (Figure 1C), confirming efficient deletion of PDGFRα (Figure 5D, arrows indicate YFP⁺PDGFRα^{High} stromal cells, and arrowheads indicates YFP⁺PDGFR α^{-} stromal cells). Most YFP⁺ cells in the small intestine of LTBR^{△PDGFRa/YÉP} mice were PDGFR α^{-} Pdpn^{low}, had lost their subepithelial position, and accumulated in the lower part of the lamina propria (Figures 5E and S5C). As a fraction of YFP⁺ cells still expressed low but detectable levels of PDGFRa, consistent with gradual excision (Figures 5F and S5D), we performed RNA-seq to investigate molecular changes occurring in a single stromal lineage, in vivo, following deletion of PDGFRa. We identified a total of 809 differentially regulated genes between YFP⁺PDGFR α^+ and YFP⁺PDGFR α^- stromal cells isolated from the small intestine of $\text{LTBR}^{{\scriptstyle \bigtriangleup}\text{PDGFRa/YFP}}$ mice, indicating that the removal of $PDGFR\alpha$ has a major impact on the transcriptome of the LTBR stromal lineage. Consistent with a role in cell proliferation, YFP⁺ cells lacking PDGFRα downregulated genes involved in cell proliferation (Mki67, Cdk1, and Cdk6) and upregulated genes involved in cell cycle arrest (Gas1, Cdkn1a, and Cdkn1c). Accordingly, PDGF-AA increased expression of proliferation and prosurvival markers such as Mki67, Cdk1, and Bcl2 in PDGFR α^+ stromal cells *in vitro* (Figure S5E). In addition, major genes essential for epithelial differentiation such as Bmp5, Bmp6, Ptch1, and Frzb and enzymes involved in RA synthesis such as Aldh1a2, Aldh1a3, and Rdh10 were downregulated in YFP⁺PDGFR α^{-} stromal cells, compared with YFP⁺PDGFR α^{+}

Cell Stem Cell Article

stromal cells, whereas BMP inhibitors Grem1 and Grem2 and Wnt regulators Dkk2, Rspo3, and Cd81 were upregulated (Figure 5G). Other downregulated genes included II33, which promotes epithelial differentiation and type 2 Immunity (Allen and Sutherland, 2014; Mahapatro et al., 2016), as well as components of the basement membrane and ECM anchoring proteins such as laminins, collagen IV, and collagen VI, respectively. In contrast, ECM fibrillar collagens such as Col1a and matricellular proteins Sparc and Sparcl1 were upregulated. These data demonstrate that PDGFRa has a predominant role in the survival, localization, and proper maturation of the LTBR stromal lineage and overall shaping of the subepithelial niche. To further determine whether PDGFRa is required for the expansion of the YFP lineage during injury (Figure 2D), we injected indomethacin in LTBR^{APDGFRa/YFP} mice. We observed rare YFP⁺ki67⁻ cells that remained within the ulcer's borders and did not migrate and expand within the injured zone (Figure 5H), as in LTBR^{YFP} mice (Figure 2D), demonstrating that PDGFRα is required for the function of the LTBR stromal lineage after injury. Finally, as PDGF-AA is one of the main ligands of PDGFRa, we investigated Pdgfa expression in intestinal populations. We observed that Pdgfa is expressed at higher levels in intestinal epithelial cells compared with other cells of the lamina propria, although perivascular cells such as pericytes and vascular smooth muscle cells also express detectable levels (Figures 5I and S5F). Single-cell analysis of the small intestinal epithelium (Haber et al., 2017) further indicated that most intestinal epithelial subsets express Pdgfa, suggesting a major role for epithelial cells in shaping their own subepithelial niche (Figure 5J). As ISCs and TA cells are major expressers of Pdgfa, it suggests a feedback control mechanism to control stem cell proliferation. Of note. additional ligands of PDGFRa, such as Pdgfc, are expressed by intestinal smooth muscle cells (Figure S5F). As Pdgfb is expressed by blood endothelial cells (Figure S5G), this further suggests tight control of YFP+ cells, which also express Pdgfrb (Figure 2B), by PDGFR ligands availability and proximity within the intestine. In line with their postnatal development, we detected a peak of expression of Pdgfa and Pdgfb in the small intestine the first week after birth, whereas Pdgfc increased between weeks 1 and 3 (Figure S5H). Overall, these data show that PDGFRa is required for maturation, localization, and function of the postnatal LTBR lineage in the small intestine at steady state and after tissue damage.

DISCUSSION

Postnatal development of the intestinal barrier requires coordinated epithelial and immune maturation. Here, we show that a subset of intestinal PDGFR α^+ stromal progenitors expressing LT β R after birth play an essential role in this process by generating a prodifferentiation and immunoregulatory stromal niche within the growing villus. We demonstrate that development, maturation, and spatial organization of the LTBR lineage requires

⁽J) Expression of *Pdgfa* in single cells of the small intestinal epithelium (https://singlecell.broadinstitute.org/single_cell/study/SCP44/small-intestinal-epithelium) (Haber et al., 2017).

In (C) and (I), data are represented as mean \pm SD. In (E) and (H), a representative image from 3 to 4 independent experiments is shown. *p < 0.05, **p < 0.01, as determined by unpaired Student's t test. U, Ulcer; C, Crypt; V, Villus; LECs, lymphatic endothelial cells; BECs, blood endothelial cells. Scale bars, 50 μ m. See also Figure S5.

PDGFR α , and failure for such postnatal stromal maturation leads to reduced postnatal growth, dysregulated intestinal homeostasis, and response to injury.

In contrast to PDGFR α^+ stromal cells that are already present in fetal intestine, the LTBR lineage develops and expands in the first few weeks after birth in the small intestine. The postnatal period coincides with major structural and functional intestinal changes, including restriction of proliferative epithelial cells within the crypts, promotion of epithelial differentiation along the villi, as well as homing and differentiation of immune populations essential for intestinal immunity (Bry et al., 1994; Chin et al., 2017). Transcriptomic profiling indicated that the LTBR lineage overexpresses several soluble and structural factors essential for this process. In agreement with previous reports (McCarthy et al., 2020), the LTBR lineage expresses high levels of PDGFRa, Pdpn, and BMPs. In addition, the LTBR stromal lineage is enriched in transcripts coding for key factors in cell differentiation, such as RA, components of the basement membrane and ECM anchoring meshwork, as well as pericyte markers, consistent with their perivascular localization (Powell et al., 2011). As the LTBR lineage is wrapped around subepithelial capillaries, it is localized in a strategic position to sense and respond to both epithelial cells and circulating factors. In contrast, PDGFR α^+ stromal cells not derived from $LT\beta R^+$ progenitors overexpressed factors promoting stem cells maintenance, including BMP inhibitors, the Wnt signaling coactivators Rspo2/Rspo3, the pericryptal stromal markers Cd81 and Cd34, as well as chemokines, cytokines, and ECM proteins with essential roles in matrix remodeling and inflammation (Stzepourginski et al., 2017; McCarthy et al., 2020; Hageman et al., 2020). Consistent with the massive colonization of the intestine by the microbiota at birth, we show that the microbiota promotes development of the LTBR lineage. It remains to be assessed whether this effect is direct or indirect, as the microbiota regulates several intestinal components including immune cells, epithelial cells, and the vasculature (Al Nabhani and Eberl, 2020; Reinhardt et al., 2012; Schirbel et al., 2013; Stappenbeck et al., 2002), which might impact on stromal cells.

Our data are in agreement with previous reports showing that PDGFRa and PDGF-AA have an essential role in intestinal morphogenesis (Karlsson et al., 2000) and further show that postnatal intestinal maturation requires differentiation of a subset of PDGFR α^+ stromal cells to restrict ISC proliferation and promote adult intestinal barrier function. This requires soluble factors that antagonize Wnts as well as other local and structural factors such as matrix proteins constituting the basement membrane, which is required for proper epithelial differentiation and integrity (Gjorevski et al., 2016; Groulx et al., 2011; Simon-Assmann et al., 1998), and RA, which has key roles in epithelial differentiation and intestinal immunity (Oliveira et al., 2018; Lukonin et al., 2020). Accordingly, RA signaling plays an essential role in epithelial homeostasis by regulating exit from epithelial regenerative state and driving enterocyte differentiation (Lukonin et al., 2020) and is a determinant factor inducing anti-inflammatory CD103⁺CD11b⁺ RA-producing DCs in the small intestine (Bakdash et al., 2015; Agace and Persson, 2012). Although RA is also produced by epithelial cells, our observations that a majority of CD103⁺CD11b⁺ DCs are localized in close proximity to YFP⁺



cells and that stromal cells isolated from LTBR^{△PDGFRa} mice have a decreased capacity to maintain CD103⁺CD11b⁺ DCs suggests that the subepithelial stromal niche plays a role in this process. In line with our results, intestinal Pdpn⁺ stromal cells produce RA and induce RA synthesis in DCs *in vitro* (Vicente-Suarez et al., 2015).

We further demonstrate that $\mathsf{PDGFR}\alpha$ is required for the fate and function of the LTBR lineage at steady state and after injury. Conditional knockout of PDGFRa in the postnatal LTBR lineage results in a 50% decrease in the cell population, consistent with previous reports showing a role for PDGFRa in mesenchymal cell survival and proliferation (Karlsson et al., 2000; Li and Hoyle, 2001; Zhuo et al., 2006). In addition, the LTBR stromal lineage lacking PDGFRa had lost its subepithelial localization within the villi, in line with major transcriptomic changes showing downregulation of BMPs, Hh signaling, collagen IV, and laminins, although overexpressing prostemness genes such as BMP antagonists, as well as proinflammatory and profibrotic genes such as II6, Sparc, and Col1a. In agreement with these findings, BMP4 and BMP5 expression is decreased in the lamina propria of newborn PDGFRa KO mice (Karlsson et al., 2000), and constitutive activation of PDGFRa signaling induces fibrosis (Olson and Soriano, 2009). PDGFRa also promoted expression of genes with immunomodulatory roles, such as RA enzyme synthesis and IL-33, a cytokine inducing type 2 immunity and involved in differentiation of goblet cells (Oliveira et al., 2018; Mahapatro et al., 2016), indicating that PDGFRa stromal expression has a major impact on tissue function. Our in vivo data showing increased epithelial proliferation, decreased generation of goblet cells, and dysregulation of DCs are consistent with these transcriptomic changes. Overall, these data show that PDGFRa is, directly or indirectly, required for development, maturation, and spatial organization of the postnatal LTBR stromal lineage. As the LTBR lineage revert to an immature prostemness phenotype in the absence of PDGFRa, both at the transcriptomic level and localization, our data support the hypothesis that a subset of postnatal PDGFRα⁺ stromal cells expressing LTβR acquire prodifferentiation and immunoregulatory functions to ensure postnatal intestinal maturation. These data also show that stromal cells function is impacted by cross talk with their microenvironment through PDGFRa.

We further show that LTBR^{△PDGFRa} mice have dysregulated repair responses. These data are consistent with dysregulation of the stromal niche, as the LTBR lineage did not develop properly in absence of PDGFRa, and the remaining PDGFRa⁻ LTBR lineage reverted to an immature phenotype (Figure 5). We hypothesized that the defect of maturation of the LTBR lineage does not counterbalance the inflammatory/regenerative signals produced by PDGFRa⁺YFP⁻ stromal cells, resulting in dysregulated regenerative and inflammatory responses. These data are in line with increasing evidence that similar pathways are engaged in inflammation and regeneration (Hageman et al., 2020) and show that PDGFR α^+ intestinal stromal cells play an essential role in this cross talk. In agreement with this hypothesis, Grem1⁺PDGFR α^+ stromal cells expressing *ll1r1* (therefore, similar to YFP⁻ cells) promote intestinal regeneration mediated by Rspo3 (Cox et al., 2021). The immature state of epithelial cells in LTBR $^{{\scriptscriptstyle \bigtriangleup} PDGFRa}$ mice, including decrease in goblet cells and tight junctions, as well as dysregulation of RA signaling might



lead to dysregulated repair and increased susceptibility to intestinal inflammation (Kim and Ho, 2010; Van der Sluis et al., 2006; Collins et al., 2011). The basement membrane, and in particular laminins, are dysregulated in inflammatory bowel diseases (Spenlé et al., 2012), suggesting that dysregulated stromal maturation overall impacts on inflammation through several mechanisms.

Finally, we show that the main ligand of PDGFR α , *Pdgfa*, is strongly produced by epithelial cells, suggesting that subepithelial PDGFR α^+ stromal cells integrate signals from the epithelium to promote anti-inflammatory responses and epithelial integrity, both of which are essential for development of the intestinal barrier. As the LTBR lineage is perivascular and coexpresses PDGFR β , proximity and availability of several PDGF ligands including PDGF-AA, PDGF-BB, and PDGF-C within the subepithelial and perivascular space is most likely key for proper position and function. Overall, these data suggest a tight control of the LTBR lineage by several mechanisms to ensure a timed development in the first few weeks after birth, when the intestine undergoes rapid villus and vascular remodeling to fulfill nutrient requirement, in order to promote intestinal barrier maturation and postnatal growth.

Limitations of the study

This study relies on BAC-transgenic fluorescent reporters, which serve as surrogates to evaluate cell identity and function by lineage tracing analysis. Specifically, we use LTBR to trace discrete perivascular stromal progenitors in the intestine, as previous reports have shown that LTBR-expressing perivascular stromal cells have progenitor functions in other organs. Further experiments will be required to determine whether LTBR is involved in regulation of stemness and cell fate of PDFGRa⁺ postnatal progenitors, opening the possibility of additional control of intestinal stromal regulation by lymphotoxin $\alpha 1\beta 2$ producing leucocytes, such as B cells, activated T cells, NK, or DCs. Moreover, the specific niche signals involved in the development and regulation of functionally distinct stromal lineages are still to be discovered.

STAR * METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Mice
 - Mice treatment
- METHOD DETAILS
 - Tissue preparation and immunostaining
 - Cell isolation and flow cytometry
 - RNA Isolation and qRT-PCR
 - RNA sequencing
 - Cell culture
- QUANTIFICATION AND STATISTICAL ANALYSIS

Cell Stem Cell Article

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j. stem.2022.04.005.

ACKNOWLEDGMENTS

We thank all members of the Stroma, Inflammation & Tissue Repair Unit, as well as members from Microenvironment & Immunity Unit, for discussions; the Mouse Genetics Engineering Platform, the Cytometry Platform, and the ICM Institute for excellent technical support; and Jeffrey Browning for the kind gift of LT β R-Ig. J.-M.J., I.S., and A.B. were funded by fellowships from Le Ministère de l'Enseignement Supérieur et de la Recherche and Fondation pour la Recherche Médicale (FRM). This work has received funding from the Institut Pasteur, INSERM and the European Union's Horizon 2020 research and innovation program (ERC Consolidator grant No. 648428) to L.P.

AUTHOR CONTRIBUTIONS

Conceptualization, methodology, and validation, J.-M.J. and L.P.; mice experiments and data analysis, I.S., S.E.D.C., A.L., P.D.N., G.N., J.-M.J., and L.P.; RNA-seq analysis, R.L., H.V., and E.K.; single-cells analysis from public data, A.B.; writing – original draft, J.-M.J. and L.P.; funding acquisition, L.P.; supervision, L.P.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: July 6, 2021 Revised: January 18, 2022 Accepted: April 7, 2022 Published: May 5, 2022

SUPPORTING CITATIONS

The following references appear in the supplemental information: Garcia et al., 2009; Nigro et al., 2014.

REFERENCES

Agace, W.W., and Persson, E.K. (2012). How vitamin A metabolizing dendritic cells are generated in the gut mucosa. Trends Immunol. 33, 42–48.

Al Nabhani, Z., and Eberl, G. (2020). Imprinting of the immune system by the microbiota early in life. Mucosal Immunol. *13*, 183–189.

Allen, J.E., and Sutherland, T.E. (2014). Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin. Semin. Immunol. *26*, 329–340.

Aoki, R., Shoshkes-Carmel, M., Gao, N., Shin, S., May, C.L., Golson, M.L., Zahm, A.M., Ray, M., Wiser, C.L., Wright, C.V.E., and Kaestner, K.H. (2016). Foxl1-expressing mesenchymal cells constitute the intestinal stem cell niche. Cell. Mol. Gastroenterol. Hepatol. *2*, 175–188.

Bakdash, G., Vogelpoel, L.T., Van Capel, T.M., Kapsenberg, M.L., and De Jong, E.C. (2015). Retinoic acid primes human dendritic cells to induce guthoming, IL-10-producing regulatory T cells. Mucosal Immunol. *8*, 265–278.

Barker, N., Van Es, J.H., Kuipers, J., Kujala, P., Van Den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., and Clevers, H. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature *449*, 1003–1007.

Batts, L.E., Polk, D.B., Dubois, R.N., and Kulessa, H. (2006). Bmp signaling is required for intestinal growth and morphogenesis. Dev. Dyn. 235, 1563–1570.

Bénézech, C., Mader, E., Desanti, G., Khan, M., Nakamura, K., White, A., Ware, C.F., Anderson, G., and Caamaño, J.H. (2012). Lymphotoxin-beta receptor signaling through NF-kappaB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells. Immunity *37*, 721–734.



Bénézech, C., White, A., Mader, E., Serre, K., Parnell, S., Pfeffer, K., Ware, C.F., Anderson, G., and Caamaño, J.H. (2010). Ontogeny of stromal organizer cells during lymph node development. J. Immunol. *184*, 4521–4530.

Bry, L., Falk, P., Huttner, K., Ouellette, A., Midtvedt, T., and Gordon, J.I. (1994). Paneth cell differentiation in the developing intestine of normal and transgenic mice. Proc. Natl. Acad. Sci. USA *91*, 10335–10339.

Chin, A.M., Hill, D.R., Aurora, M., and Spence, J.R. (2017). Morphogenesis and maturation of the embryonic and postnatal intestine. Semin. Cell Dev. Biol. 66, 81–93.

Collins, C.B., Aherne, C.M., Kominsky, D., Mcnamee, E.N., Lebsack, M.D., Eltzschig, H., Jedlicka, P., and Rivera-Nieves, J. (2011). Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology *141*, 1821–1831.

Coombes, J.L., Siddiqui, K.R.R., Arancibia-Cárcamo, C.V., Hall, J., Sun, C.-M., Belkaid, Y., and Powrie, F. (2007). A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF- β - and retinoic acid–dependent mechanism. J. Exp. Med. 204, 1757–1764.

Cox, C.B., Storm, E.E., Kapoor, V.N., Chavarria-Smith, J., Lin, D.L., Wang, L., Li, Y., Kljavin, N., Ota, N., Bainbridge, T.W., et al. (2021). IL-1R1-dependent signaling coordinates epithelial regeneration in response to intestinal damage. Sci. Immunol. *6*, eabe8856.

Degirmenci, B., Valenta, T., Dimitrieva, S., Hausmann, G., and Basler, K. (2018). GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. Nature *558*, 449–453.

Di Carlo, S.E., and Peduto, L. (2018). The perivascular origin of pathological fibroblasts. J. Clin. Invest. *128*, 54–63.

Ewels, P., Magnusson, M., Lundin, S., and Käller, M. (2016). MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics *32*, 3047–3048.

Fütterer, A., Mink, K., Luz, A., Kosco-Vilbois, M.H., and Pfeffer, K. (1998). The lymphotoxin b receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity *9*, 59–70.

Garcia, M.I., Ghiani, M., Lefort, A., Libert, F., Strollo, S., and Vassart, G. (2009). LGR5 deficiency deregulates Wht signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev. Biol. *331*, 58–67.

Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M.E., Ordóñez-Morán, P., Clevers, H., and Lutolf, M.P. (2016). Designer matrices for intestinal stem cell and organoid culture. Nature *539*, 560–564.

Greicius, G., Kabiri, Z., Sigmundsson, K., Liang, C., Bunte, R., Singh, M.K., and Virshup, D.M. (2018). *PDGFR* α ⁺ pericryptal stromal cells are the critical source of Wnts and RSPO3 for murine intestinal stem cells *in vivo*. Proc. Natl. Acad. Sci. USA *115*, E3173–E3181.

Groulx, J.F., Gagné, D., Benoit, Y.D., Martel, D., Basora, N., and Beaulieu, J.F. (2011). Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. *30*, 195–206.

Haber, A.L., Biton, M., Rogel, N., Herbst, R.H., Shekhar, K., Smillie, C., Burgin, G., Delorey, T.M., Howitt, M.R., Katz, Y., et al. (2017). A single-cell survey of the small intestinal epithelium. Nature *551*, 333–339.

Hadis, U., Wahl, B., Schulz, O., Hardtke-Wolenski, M., Schippers, A., Wagner, N., Müller, W., Sparwasser, T., Förster, R., and Pabst, O. (2011). Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity *34*, 237–246.

Hageman, J.H., Heinz, M.C., Kretzschmar, K., Van Der Vaart, J., Clevers, H., and Snippert, H.J.G. (2020). Intestinal regeneration: regulation by the microenvironment. Dev. Cell *54*, 435–446.

Hoch, R.V., and Soriano, P. (2003). Roles of PDGF in animal development. Development *130*, 4769–4784.

Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C., and Song, S.Y. (2004). Retinoic acid imprints gut-homing specificity on T cells. Immunity *21*, 527–538.

Jiang, D., Liang, J., and Noble, P.W. (2007). Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 23, 435–461.

Karlsson, L., Lindahl, P., Heath, J.K., and Betsholtz, C. (2000). Abnormal gastrointestinal development in PDGF-A and PDGFR-(alpha) deficient mice

implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development *127*, 3457–3466.

Kim, Y.S., and Ho, S.B. (2010). Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 12, 319–330.

Kim, I., Yilmaz, O.H., and Morrison, S.J. (2005). CD144 (VE-cadherin) is transiently expressed by fetal liver hematopoietic stem cells. Blood *106*, 903–905. https://doi.org/10.1182/blood-2004-12-4960.

Koh, S.J., Choi, Y., Kim, B.G., Lee, K.L., Kim, D.W., Kim, J.H., Kim, J.W., and Kim, J.S. (2016). Matricellular protein Periostin mediates intestinal inflammation through the activation of nuclear factor kappa B signaling. PLoS One *11*, e0149652.

Kosinski, C., Li, V.S.W., Chan, A.S.Y., Zhang, J., Ho, C., Tsui, W.Y., Chan, T.L., Mifflin, R.C., Powell, D.W., Yuen, S.T., et al. (2007). Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. USA *104*, 15418–15423.

Kosinski, C., Stange, D.E., Xu, C., Chan, A.S., Ho, C., Yuen, S.T., Mifflin, R.C., Powell, D.W., Clevers, H., Leung, S.Y., and Chen, X. (2010). Indian hedgehog regulates intestinal stem cell fate through epithelial-mesenchymal interactions during development. Gastroenterology *139*, 893–903.

Köster, J., and Rahmann, S. (2012). Snakemake—a scalable bioinformatics workflow engine. Bioinformatics 28, 2520–2522.

Krautler, N.J., Kana, V., Kranich, J., Tian, Y., Perera, D., Lemm, D., Schwarz, P., Armulik, A., Browning, J.L., Tallquist, M., et al. (2012). Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell *150*, 194–206.

Kuo, H.J., Maslen, C.L., Keene, D.R., and Glanville, R.W. (1997). Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J. Biol. Chem. *272*, 26522–26529.

Laffont, S., Siddiqui, K.R., and Powrie, F. (2010). Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells. Eur. J. Immunol. *40*, 1877–1883.

Lantier, L., Lacroix-Lamandé, S., Potiron, L., Metton, C., Drouet, F., Guesdon, W., Gnahoui-David, A., Le Vern, Y., Deriaud, E., Fenis, A., et al. (2013). Intestinal CD103+ dendritic cells are key players in the innate immune control of Cryptosporidium parvum infection in neonatal mice. PLoS Pathog. *9*, e1003801.

Li, J., and Hoyle, G.W. (2001). Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells. Dev. Biol. *239*, 338–349.

Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. *15*, 550.

Lu, T.T., and Browning, J.L. (2014). Role of the lymphotoxin/LIGHT system in the development and maintenance of reticular networks and vasculature in lymphoid tissues. Front. Immunol. *5*, 47.

Lukonin, I., Serra, D., Challet Meylan, L., Volkmann, K., Baaten, J., Zhao, R., Meeusen, S., Colman, K., Maurer, F., Stadler, M.B., et al. (2020). Phenotypic landscape of intestinal organoid regeneration. Nature *586*, 275–280.

Macho-Fernandez, E., Koroleva, E.P., Spencer, C.M., Tighe, M., Torrado, E., Cooper, A.M., Fu, Y.X., and Tumanov, A.V. (2015). Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells. Mucosal Immunol. *8*, 403–413.

Mahapatro, M., Foersch, S., Hefele, M., He, G.W., Giner-Ventura, E., Mchedlidze, T., Kindermann, M., Vetrano, S., Danese, S., Günther, C., et al. (2016). Programming of intestinal epithelial differentiation by IL-33 derived from pericryptal fibroblasts in response to systemic infection. Cell Rep. *15*, 1743–1756.

Mccarthy, N., Manieri, E., Storm, E.E., Saadatpour, A., Luoma, A.M., Kapoor, V.N., Madha, S., Gaynor, L.T., Cox, C., Keerthivasan, S., et al. (2020). Distinct mesenchymal cell populations generate the essential intestinal BMP signaling gradient. Cell Stem Cell *26*, 391–402.e5.

Muncan, V., Heijmans, J., Krasinski, S.D., Büller, N.V., Wildenberg, M.E., Meisner, S., Radonjic, M., Stapleton, K.A., Lamers, W.H., Biemond, I., et al. (2011). Blimp1 regulates the transition of neonatal to adult intestinal epithelium. Nat. Commun. *2*, 452.





Ng, Y.L., Klopcic, B., Lloyd, F., Forrest, C., Greene, W., and Lawrance, I.C. (2013). Secreted protein acidic and rich in cysteine (SPARC) exacerbates colonic inflammatory symptoms in dextran sodium sulphate-induced murine colitis. PLoS One 8, e77575.

Nigro, G., Rossi, R., Commere, P.H., Jay, P., and Sansonetti, P.J. (2014). The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe *15*, 792–798.

Noah, T.K., Donahue, B., and Shroyer, N.F. (2011). Intestinal development and differentiation. Exp. Cell Res. *317*, 2702–2710.

Oliveira, L.M., Teixeira, F.M.E., and Sato, M.N. (2018). Impact of retinoic acid on immune cells and inflammatory diseases. Mediators Inflamm. *2018*, 3067126.

Olson, L.E., and Soriano, P. (2009). Increased PDGFR α activation disrupts connective tissue development and drives systemic fibrosis. Dev. Cell *16*, 303–313.

Peduto, L., Dulauroy, S., Lochner, M., Späth, G.F., Morales, M.A., Cumano, A., and Eberl, G. (2009). Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. *182*, 5789–5799.

Perez-Shibayama, C., Gil-Cruz, C., and Ludewig, B. (2019). Fibroblastic reticular cells at the nexus of innate and adaptive immune responses. Immunol. Rev. 289, 31–41.

Persson, E.K., Scott, C.L., Mowat, A.M., and Agace, W.W. (2013). Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur. J. Immunol. *43*, 3098–3107.

Powell, D.W., Pinchuk, I.V., Saada, J.I., Chen, X., and Mifflin, R.C. (2011). Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. *73*, 213–237.

Qi, Z., Li, Y., Zhao, B., Xu, C., Liu, Y., Li, H., Zhang, B., Wang, X., Yang, X., Xie, W., et al. (2017). BMP restricts stemness of intestinal Lgr5+ stem cells by directly suppressing their signature genes. Nat. Commun. 8, 13824.

Reinhardt, C., Bergentall, M., Greiner, T.U., Schaffner, F., Ostergren-Lundén, G., Petersen, L.C., Ruf, W., and Bäckhed, F. (2012). Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature *483*, 627–631.

Rennert, P.D., James, D., Mackay, F., Browning, J.L., and Hochman., P.S. (1998). Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity *9*, 71–79. https://doi.org/10.1016/s1074-7613(00) 80589-0.

Ruane, D.T., and Lavelle, E.C. (2011). The role of CD103(+) dendritic cells in the intestinal mucosal immune system. Front. Immunol. 2, 25.

Sartor, R.B. (1997). Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment. Pharmacol. Ther. *11*, 89–96. discussion 96–97.

Schirbel, A., Kessler, S., Rieder, F., West, G., Rebert, N., Asosingh, K., Mcdonald, C., and Fiocchi, C. (2013). Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology *144*, 613–623.e9.

Schönig, K., Schwenk, F., Rajewsky, K., and Bujard, H. (2002). Stringent doxycycline dependent control of CRE recombinase *in vivo*. Nucleic Acids Res. *30*, e134.

Schuijers, J., Van Der Flier, L.G., Van Es, J., and Clevers, H. (2014). Robust cremediated recombination in small intestinal stem cells utilizing the olfm4 locus. Stem Cell Rep. *3*, 234–241.

Schulz, O., Jaensson, E., Persson, E.K., Liu, X., Worbs, T., Agace, W.W., and Pabst, O. (2009). Intestinal CD103+, but not CX3CR1+, antigen sampling cells

migrate in lymph and serve classical dendritic cell functions. J. Exp. Med. 206, 3101–3114.

Shoshkes-Carmel, M., Wang, Y.J., Wangensteen, K.J., Tóth, B., Kondo, A., Massasa, E.E., Itzkovitz, S., and Kaestner, K.H. (2018). Subepithelial telocytes are an important source of Whts that supports intestinal crypts. Nature 557, 242–246.

Sigthorsson, G., Simpson, R.J., Walley, M., Anthony, A., Foster, R., Hotz-Behoftsitz, C., Palizban, A., Pombo, J., Watts, J., Morham, S.G., and Bjarnason, I. (2002). COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology *122*, 1913–1923.

Simon-Assmann, P., Lefebvre, O., Bellissent-Waydelich, A., Olsen, J., Orian-Rousseau, V., and De Arcangelis, A. (1998). The laminins: role in intestinal morphogenesis and differentiation. Ann. N. Y. Acad. Sci. 859, 46–64.

Sparwasser, T., Gong, S., Li, J.Y.H., and Eberl, G. (2004). General method for the modification of different BAC types and the rapid generation of BAC transgenic mice. Genesis *38*, 39–50.

Spenlé, C., Hussenet, T., Lacroute, J., Lefebvre, O., Kedinger, M., Orend, G., and Simon-Assmann, P. (2012). Dysregulation of laminins in intestinal inflammation. Pathol. Biol. (Paris) 60, 41–47.

Srinivas, S., Watanabe, T., Lin, C.S., William, C.M., Tanabe, Y., Jessell, T.M., and Costantini, F. (2001). Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. *1*, 4.

Stappenbeck, T.S., Hooper, L.V., and Gordon, J.I. (2002). Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. USA *99*, 15451–15455.

Stzepourginski, I., Eberl, G., and Peduto, L. (2015). An optimized protocol for isolating lymphoid stromal cells from the intestinal lamina propria. J. Immunol. Methods *421*, 14–19.

Stzepourginski, I., Nigro, G., Jacob, J.M., Dulauroy, S., Sansonetti, P.J., Eberl, G., and Peduto, L. (2017). CD34+ mesenchymal cells are a major component of the intestinal stem cells niche at homeostasis and after injury. Proc. Natl. Acad. Sci. USA *114*, E506–E513.

Tanoue, T., Atarashi, K., and Honda, K. (2016). Development and maintenance of intestinal regulatory T cells. Nat. Rev. Immunol. *16*, 295–309.

Van Der Flier, L.G., and Clevers, H. (2009). Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241–260.

Van Der Flier, L.G., Van Gijn, M.E., Hatzis, P., Kujala, P., Haegebarth, A., Stange, D.E., Begthel, H., Van Den Born, M., Guryev, V., Oving, I., et al. (2009). Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell *136*, 903–912.

Van Der Sluis, M., De Koning, B.A.E., De Bruijn, A.C.J.M., Velcich, A., Meijerink, J.P.P., Van Goudoever, J.B., Büller, H.A., Dekker, J., Van Seuningen, I., Renes, I.B., and Einerhand, A.W.C. (2006). Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology *131*, 117–129.

Varet, H., Brillet-Guéguen, L., Coppée, J.Y., and Dillies, M.A. (2016). SARTools: a DESeq2- and EdgeR-based R pipeline for comprehensive differential analysis of RNA-Seq data. PLoS One *11*, e0157022.

Vicente-Suarez, I., Larange, A., Reardon, C., Matho, M., Feau, S., Chodaczek, G., Park, Y., Obata, Y., Gold, R., Wang-Zhu, Y., et al. (2015). Unique lamina propria stromal cells imprint the functional phenotype of mucosal dendritic cells. Mucosal Immunol 8, 141–151.

Zhuo, Y., Hoyle, G.W., Shan, B., Levy, D.R., and Lasky, J.A. (2006). Overexpression of PDGF-C using a lung specific promoter results in abnormal lung development. Transgen. Res. *15*, 543–555.



KEY RESOURCES TABLE

Antibodies PE-conjugated anti-podoplanin (6.1.1) Biol.egend Cat# 127407;RRIDAB_2161929 PR-conjugated anti-Codoplanin (6.1.1) Gift fron J. Browning N/A BV786-conjugated anti-CD31 (380) BD Biosciences Cat# 74087; RRIDAB_2740529 APC-conjugated anti-CD31 (380) BD Biosciences Cat# 54122; RRIDAB_221589 Babbi anti-GPT [polycional] ThermoFischer Cat# 54120; RRIDAB_2115401 Biotrylated anti-DDGFRa (APAS) ThermoFischer Cat# 13-1401.28, RRIDAB_268697 Batabit anti-GPOGRa (Dylocinal) RAD System Cat# ActiSi2, RRIDAB_284118 Batabit anti-GPOGRa (Dylocinal) ThermoFischer Cat# ActiSi2, RRIDAB_284118 Batabit anti-GPOGRa (Dylocinal) ThermoFischer Cat# 41512; RRIDAB_284867 Att anti-Coonjugated anti-CD10; (M16) ThermoFischer Cat# 4174037, RRIDAB_284867 Att anti-Coonjugated anti-CD10; (M16) ThermoFischer Cat# 4174037, RRIDAB_284367 APC-conjugated anti-CD19 Biol.egend Cat# 40028; RRIDAB_2824367 APC-Conjugated anti-CD19 Biol.egend Cat# 10228; RRIDAB_242; RRIDAB_22324367 BV785-conjugated anti-MC-II (M5/ ThermoFischer Cat# 10716; RRIDAB_27271 BV685-conjugated anti-MC-II (M5/ ThermoFischer Cat# 10716; RRIDAB_27271 BV785-conjugated anti-MC-II (M5/ ThermoFischer Cat# 10716; RRIDAB_27271	REAGENT or RESOURCE	SOURCE	IDENTIFIER
PF-conjugated anti-padoplanin (8.1.1) Biologend Catt 127407;RRID:AB_2161929 Syrian hamster anti-padoplanin (8.1.1) Gift from J. Browning N/A WVRB-conjugated anti-C031 (MEC.13.3) BD Biosciences Catt 740879; RRID:AB_2398497 RAFC-conjugated anti-C031 (MEC.13.3) BD Biosciences Catt 562420; RRID:AB_2989497 Rabbit anti-GPD (polyclonal) ThermoFischer Catt 13-1401-82; RRID:AB_24569 PF-Texas-Red-conjugated anti-C045 BD Biosciences Catt 562420; RRID:AB_11154401 S0-F11) Catt 14-122; RRID:AB_466607 Gatt anti-PDGFRa (APAS) ThermoFischer Catt 13-1401-82; RRID:AB_466607 Gatt anti-PDGFRa (bolyclonal) RAD System Catt A11512; RRID:AB_288897 Rat anti-E-Catherin (DECMA-1) Abcam Catt A11512; RRID:AB_288897 Rat anti-E-Catherin (DECMA-1) Abcam Catt A11512; RRID:AB_2384867 APC-conjugated anti-C015 (AFSC11) Biologend Catt 100311; RRID:AB_2384867 APC-conjugated anti-C0162; RRID:AB_20384867 APC-conjugated anti-C0162; RRID:AB_2384867 APC-conjugated anti-C016 (AFSC11) Biologend Catt 100311; RRID:AB_312876 DVRSD-conjugated anti-C016 (M478) ThermoFischer Catt 103311; RRID:AB_312876 DVRSD-conjugated anti-C016 (M478) ThermoFischer Catt 103311; RRID:AB_2384867 APC-6F780-conjugated anti-C0116 (M479) BD Biosciences Catt 563087; RRID:AB_25820897 APC-6F780-conjugated anti-C0116 (M479) BD Biosciences Catt 563087; RRID:AB_2722581 EV785-conjugated anti-C0116 (M479) BD Biosciences Catt 563087; RRID:AB_2722581 EV785-conjugated anti-C0116 (M479) BD Biosciences Catt 563087; RRID:AB_272759 BV241-conjugated anti-C0116 (M479) BD Biosciences Catt 563087; RRID:AB_272759 BV242-conjugated anti-L0103 (M290) BD Biosciences Catt 563087; RRID:AB_272759 BV242-conjugated anti-L0103 (M290) BD Biosciences Catt 56301; RRID:AB_272759 BV242-conjugated anti-L0103 (M290) BD Biosciences Catt 563037; RRID:AB_272581 BV405-conjugated anti-L0103 (M290) BD Biosciences Catt 56301; RRID:AB_272759 BV242-conjugated anti-L0103 (M290) BD Biosciences Catt 563037; RRID:AB_212757 Br2-CP-0;0;5-conjugated anti-L020 (BD Biosciences Catt 56301; RRID:AB_212759 BV242-conjugated anti-L020 (BD Bio	Antibodies		
Syrian hamster anti-podplaini (8.1.1)Gift from J. BrowingNABV786-conjugated anti-CD31 (890)BD BiosciencesCat# 501262; RHID:AB_298497Rabbit anti-GPF (polyciona)ThermoFischerCat# 61262; RHID:AB_21569Rabbit anti-GPF (polyciona)BD BiosciencesCat# 61262; RHID:AB_21569So F11)BD BiosciencesCat# 61262; RHID:AB_2116401So Cat anti-POGFRa (APAs)ThermoFischerCat# AF1052; RHD:AB_268607Sota tant-POGFRa (APAs)RAD SystemCat# AF1652; RHD:AB_286807Sota tant-POGFRa (APAs)ThermoFischerCat# AF1652; RHD:AB_286807Babit anti-Lyacyme1 (polyciona)RAD SystemCat# AF1658; RHD:AB_286807Meet Gern AgglutininThermoFischerCat# AF1658; RHD:AB_288897APC-conjugated anti-CD11 (M418)ThermoFischerCat# 100719162; RHD:AB_288487APC-Gri0gated anti-CD11c (M418)ThermoFischerCat# 47-0114-82; RRD:AB_1548652RTC-conjugated anti-CD13 (M290)BD BiosciencesCat# 50231; RHD:AB_272175Pe-Cy7-conjugated anti-CD14 (Mf57)BiolegendCat# 10216; RHD:AB_272175Pe-Cy7-conjugated anti-CD16 (Mf47)BiolegendCat# 10216; RHD:AB_272175Pe-Cy7-conjugated anti-CD16 (Mf47)BiolegendCat# 10216; RHD:AB_2731794Pe-Cy7-conjugated anti-S0196BiolegendCat# 10216; RHD:AB_2731794Pe-Cy7-conjugated anti-S0196BiolegendCat# 10216; RHD:AB_2731794Pe-Cy7-conjugated anti-S0196BiolegendCat# 10216; RHD:AB_2731794Pe-Cy7-conjugated anti-S01972BiolegendCat# 10216; RHD:AB_2731794PerCy7-conju	PE-conjugated anti-podoplanin (8.1.1)	BioLegend	Cat# 127407;RRID:AB_2161929
BV786-conjugated anti-CD31 (480) BD Biosciences Catf 451282, RRID:AB, 2740529 APC-conjugated anti-CD31 (MEC.13.3) BD Biosciences Catf 451282, RRID:AB, 221589 BD Biosciences Catf 55242, RRID:AB, 221589 BD Biosciences Catf 311122, RRID:AB, 221589 Biotnylated anti-DDGFRa (APAS) ThermoFischer Catf 311401-82; RRID:AB, 248067 Gatt anti-DC3 (Hand) RAD System Catf A1152; RRID:AB, 28168 Biotnylated anti-DDGFRa (APAS) ThermoFischer Catf A1152; RRID:AB, 283167 Rat anti-EC Cathfinin (DECMA-1) Abcam Catf A1151; RRID:AB, 293161 Rabbit anti-Uscorting (Locyclonal) ThermoFischer Catf 100311; RRID:AB, 312676 PAC-conjugated anti-CD1 (AV18) ThermoFischer Catf 100311; RRID:AB, 324867 APC-conjugated anti-CD110 (M170) Biolegend Catf 311-5321-82; RRID:AB, 2582097 APC-Gr00-conjugated anti-CD110 (M170) Biolegend Catf 311-5321-82; RRID:AB, 2582282 VPR8-conjugated anti-CD110 (M170) Biolegend Catf 311-5321-82; RRID:AB, 272291 VPR8-conjugated anti-CD110 (M170) Biolegend Catf 456301; RRID:AB, 2722775 Pe-CP-cy5.5-conjugated anti-L906 BD Biosciences Catf 456301; RRID:AB, 272291 VPR8-Conjugated anti-CD116 (M170) Biolegend Catf 456301; RRID:AB, 272799 VPR2-cy5.5-conjugated anti-L906 BD Bioscien	Syrian hamster anti-podoplanin (8.1.1)	Gift from J. Browning	N/A
APC-conjugated anti-CD12 (MEC.13.3)BD BiosciencesCat# A11122; RRID-AB_32B467Rabbit anti-GPP (polycional)ThermoFischerCat# A21132; RRID-AB_221569BD BiosciencesCat# 562402; RRID-AB_1115A4Cat# 562402; RRID-AB_241569BD BiosciencesCat# 15-1401-82; RRID-AB_468607Cat# A1102; RRID-AB_468607Goat anti-PDGFRa (polycional)R&D SystemCat# A1162; RRID-AB_238187Rabbit anti-Lycogymet (polycional)ThermoFischerCat# PA5-1668; RRID-AB_12984867APC-conjugated anti-CD3 (145-2C11)BiolegendCat# 700131; RRID-AB_1284867APC-conjugated anti-CD16 (M418)ThermoFischerCat# 70114-82; RRID-AB_148682PTC-conjugated anti-CD16 (M418)ThermoFischerCat# 70114-82; RRID-AB_1484862PTC-conjugated anti-CD116 (M418)ThermoFischerCat# 503817.82; RRID-AB_272175Pe-cV7-conjugated anti-CD103 (M290)BD BiosciencesCat# 503817.82; RRID-AB_272281BV685-conjugated anti-L916 (M7/0)BiolegendCat# 10216; RRID-AB_272281BV685-conjugated anti-L916BD BiosciencesCat# 503817.82; RRID-AB_2723794Pe-CP-v55-conjugated anti-L916BD BiosciencesCat# 503817.82; RRID-AB_2723794BV685-conjugated anti-L916BD BiosciencesCat# 503817.82; RRID-AB_2727175Pe-CP-v55-conjugated anti-L916BD BiosciencesCat# 505817.87; RRID-AB_272717Pe-CP-v55-conjugated anti-L916BD BiosciencesCat# 505917.87; RRID-AB_272717Pe-CP-v55-conjugated anti-L916BD BiosciencesCat# 505917.87; RRID-AB_272717Pe-CP-v55-conjugated anti-L916RID-AB_1424Sigma-Adrich<	BV786-conjugated anti-CD31 (390)	BD Biosciences	Cat# 740879; RRID:AB_2740529
Rabbit anti-GFP (polyclonal) ThermoFischer Cat# 562402; RRIDAB_1115401 PE-Texas-Red-conjugated anti-CD45 BD Biosciences Cat# 562402; RRIDAB_1115401 Biodiniyated anti-PDGFRa (APAS) ThermoFischer Cat# 131401-82; RRIDAB_2486607 Cotat anti-PDGFRa (APAS) ThermoFischer Cat# AF1062; RRIDAB_208687 Rat anti-E-Cadherin (DECMA-1) Abcam Cat# Ab11512; RRIDAB_208687 Rat anti-E-Cadherin (DeCMA-1) Abcam Cat# Ab11512; RRIDAB_2384867 APC-conjugated anti-CD3 (145-2C11) BioLegend Cat# 70014; RRIDAB_2312676 BV680-conjugated anti-CD119 BioLegend Cat# 47-0114.82; RRIDAB_23262097 PAC-6r780-conjugated anti-CD110 (M170) BioLegend Cat# 47-0114.82; RRIDAB_2562097 SV680-conjugated anti-CD103 (M290) BD Biosciences Cat# 47-0114.82; RRIDAB_2727175 SV680-conjugated anti-CD110 (M170) BioLegend Cat# 47-0148.82; RRIDAB_2727175 SV680-conjugated anti-CD110 (M170) BioLegend Cat# 4563081; RRIDAB_2727175 SV680-conjugated anti-CD110 (M170) BioLegend Cat# 4563081; RRIDAB_2727175 SV680-conjugated anti-CD110 (M170) BioLegend Cat# 4563081; RRIDAB_272713 PerCP-0y5.5-conjugated anti-Ly6G BD Biosciences Cat# 456373.42; R	APC-conjugated anti-CD31 (MEC.13.3)	BD Biosciences	Cat# 551262; RRID:AB_398497
PE-Texas-Red-conjugated anti-CD45BD BiosciencesCat# 562420; RRID:AB_11154401306-F11)Sitcinylated anti-PDGFRa (APA5)ThermoFischerCat# 13-1401-42; RRID:AB_286867Gat anti-PDGFRa (polycional)RRD SystemCat# Ab11512; RRID:AB_2328687Rat anti-E-Cadherin (DECMA-1)AbcamCat# Ab11512; RRID:AB_2328687Rabbit anti-Usosyme1 (polycional)ThermoFischerCat# 7002; RRID:AB_2328687APC-conjugated anti-CD14 (145-2C11)BioLegendCat# 00231; RRID:AB_232867VB60C-onjugated anti-CD16 (N418)ThermoFischerCat# 470238; RRID:AB_232867APC-er780-conjugated anti-CD16 (N418)ThermoFischerCat# 302238; RRID:AB_278276VB60C-onjugated anti-CD16 (N418)ThermoFischerCat# 302238; RRID:AB_2721775Pe-Cy7-conjugated anti-CD116 (N418)BD BiosciencesCat# 50307; RRID:AB_2721775Pe-Cy7-conjugated anti-CD116 (N4170)BioLegendCat# 50307; RRID:AB_2721775Pe-Cy7-conjugated anti-L916GBD BiosciencesCat# 50307; RRID:AB_2722611BV21-conjugated anti-L916GBD BiosciencesCat# 50307; RRID:AB_2721775PerCP-cy5-s-conjugated anti-L96GBioLegendCat# 10216; RRID:AB_2722611BV21-conjugated anti-L906BioLegendCat# 450201; RRID:AB_2016713PerCP-cy5-s-conjugated anti-L9076ThermoFischerCat# 450201; RRID:AB_2016713PerCP-cy5-s-conjugated anti-L9076ThermoFischerCat# 450201; RRID:AB_2016713PerCP-cy5-s-conjugated anti-L9076Sigma-AdrichCat# 45031; RRID:AB_2016713PerCP-cy5-s-conjugated anti-L9076Sigma-AdrichCat# 450321; RRID:AB_20	Rabbit anti-GFP (polyclonal)	ThermoFischer	Cat# A-11122; RRID:AB_221569
Biolinylated anti-PDGFRa (pAPA5) ThermoFischer Cat 13-1401-82; RRIDAB_466807 Goat anti-PDGFRa (polycional) RaD System Cat AP1102; RRIDAB_2236897 Ratanti-E-Cadinerin (DECMA-1) Abcam Cat AP11512; RRIDAB_238087 Ratanti-E-Cadinerin (DECMA-1) BioLegend Cat 1007162; RRIDAB_2334867 APC-conjugated anti-CD145-2C11) BioLegend Cat 1002171; RRIDAB_212676 BV650-conjugated anti-CD116 (M16) ThermoFischer Cat 44 7-0114-82; RRIDAB_2562097 APC-67780-conjugated anti-CD110 (M16) ThermoFischer Cat 44 7-0114-82; RRIDAB_2562097 APC-67780-conjugated anti-CD110 (M170) BioLegend Cat 1002171; RRIDAB_2562097 APC-67780-conjugated anti-CD110 (M170) BioLegend Cat 10231729 BV785-conjugated anti-CD103 (M290) BD Biosciences Cat 563087; RRIDAB_272175 BV645-conjugated anti-Siglec F BD Biosciences Cat 563087; RRIDAB_2722981 BV421-conjugated anti-Siglec F BD Biosciences Cat 562081; RRIDAB_2722981 BV421-conjugated anti-Siglec F BD Biosciences Cat 562081; RRIDAB_2722981 BV605-conjugated anti-Siglec F BD Biosciences Cat 562081; RRIDAB_2727949 BV605-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_2727194 BV605-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_2727194 BV605-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_2727949 BV605-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_217271 BFC7C-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_9132173 Cat 14 45-5773-82; RRIDAB_913351 FFC7C-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_91321 FFC7C-conjugated anti-Siglec F BD Biosciences Cat 127616; RRIDAB_91321 FFC7C-conjugated anti-Siglec F BD Bioscience Cat 127616; RRIDAB_91321 FFC7C-conjugated anti-Siglec F BD Bioscience Cat 127616; RRIDAB_91331 FFC7C-conjugated anti-Siglec F BD Bioscience Cat 127676 FFC7C-conjugated anti-Sigle F BD Bioscience Cat 12362 FFC7C-conjugated anti-Sigle F BD Bioscience Cat 12362 FFC7C-conjugated anti-CD4 (BM4-5) Bioscience Cat 12362 FFC7C-conjugated anti-CD4 (BM4-5) Bioscience Cat 123621-00 FFC7C-conjugated anti-CD4 (BM4-5) Bioscience Cat 1236276001 Recordinat	PE-Texas-Red-conjugated anti-CD45 (30-F11)	BD Biosciences	Cat# 562420; RRID:AB_11154401
Goat anti-PDGFRa (polyclonal)RAD SystemCat# AF1062; RRID-AB_2236897Rat anti-E-Cadherin (DECMA-1)NacamCat# AF1512; RRID-AB_238118Rat bat anti-System (polyclonal)ThermoFischerCat# AF1512; RRID-AB_2334867Wheat Germ AgglutininThermoFischerCat# VA5-1668; RRID-AB_2334867APC-conjugated anti-CD110 (M5-2C11)BioLegendCat# 47-0114-82; RRID-AB_2562097APC-erroplugated anti-CD110 (M418)ThermoFischerCat# 47-0114-82; RRID-AB_2662097APC-erroplugated anti-CD110 (M5/ThermoFischerCat# 47-0114-82; RRID-AB_2721775BV785-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID-AB_27221775BV785-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID-AB_27221775BV421-conjugated anti-LQ10 (M1/70)BioLegendCat# 563087; RRID-AB_27221775BV421-conjugated anti-LyGGBD BiosciencesCat# 562681; RRID-AB_2722781BV421-conjugated anti-LyGGBD BiosciencesCat# 562681; RRID-AB_2727319PerCP-05.5-conjugated anti-LyGGBioLegendCat# 4562681; RRID-AB_27273173PerCP-05.5-conjugated anti-Lody (RM4-5)BioLegendCat# 45-5773-82; RRID-AB_914351(FLK-65)ThermoFischerCat# 45-5773-82; RRID-AB_914271PerCP-05.5-conjugated anti-LodypeYanemoFischerCat# 45-5773-82; RRID-AB_91428PerCP-05.5-conjugated anti-LodypeYanemoFischerCat# 45-5773-82; RRID-AB_91428PerCP-05.5-conjugated anti-LodypeYanemoFischerCat# 45-5773-82; RRID-AB_91428PerCP-05.5-conjugated anti-LodypeSigma-AdrichCat# 45-5773-82; RRID-AB_9143	Biotinylated anti-PDGFRa (APA5)	ThermoFischer	Cat# 13-1401-82; RRID:AB_466607
Rat anti-L-Scadnerin (DECMA-1)AbcamCat# Ab11512; RRID:AB_298118Rabbit anti-Lysozyme 1 (polycional)ThermoFischerCat# DA5-16668; RRID:AB_10984852Mheat Gem AgglutininThermoFischerCat# ICN790162; RRID:AB_2324867APC-conjugated anti-CD3 (145-2C11)BioLegendCat# 400311; RRID:AB_312676BV650-conjugated anti-CD10 (N418)ThermoFischerCat# 47-0114-42; RRID:AB_1646822PTC-conjugated anti-CD103 (M290)BD BiosciencesCat# 47-0114-42; RRID:AB_164682PTR-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID:AB_2721775Pe-Cy7-conjugated anti-CD103 (M290)BD BiosciencesCat# 56281; RRID:AB_272799PV785-conjugated anti-Siglec FBD BiosciencesCat# 56281; RRID:AB_272799PV605-conjugated anti-Ly6GBioLegendCat# 100510; RRID:AB_272799PerCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 100510; RRID:AB_17271FITC-conjugated anti-Ly6GBioLegendCat# 100510; RRID:AB_1877271FPCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 45-6377-82; RRID:AB_194351FPCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 45-6377-82; RRID:AB_194351FITC-conjugated anti-Ly6GBioLegendCat# 45-6377-82; RRID:AB_914351FPacP-cy5.5-conjugated anti-SotypeThermoFischerCat# 45-6371-82; RRID:AB_914351FPacP-cy5.5-conjugated anti-SotypeThermoFischerCat# 45-6371-82; RRID:AB_914351FPacP-cy5.5-conjugated anti-SotypeSigma-AdrichCat# 45-6371-82; RRID:AB_914351FPacP-cy5.5-conjugated anti-SotypeSigma-AdrichCat# 45-6371-82; RRID:AB_914351	Goat anti-PDGFRa (polyclonal)	R&D System	Cat# AF1062; RRID:AB_2236897
Rabbit anti-Lysozyme1 (polycional)ThermoFischerCat# PAS-16688; RFID-AB_10948452Wheat Gerrn AgglutininThermoFischerCat# (DN790162, RRID-AB_233467)APC-conjugated anti-CD19BioLegendCat# 40211; RRID-AB_312676BW560-conjugated anti-CD110 (N18)ThermoFischerCat# 47-0114-82; RRID-AB_1548652FTC-conjugated anti-CD113 (M290)BD BiosciencesCat# 503067, RRID-AB_2721775BV650-conjugated anti-CD13 (M290)BD BiosciencesCat# 101216; RRID-AB_2722581BV785-conjugated anti-CD13 (M170)BD BiosciencesCat# 503067, RRID-AB_2722581BV805-conjugated anti-CD14 (M1770)BD BiosciencesCat# 10216; RRID-AB_2722751BV6242-conjugated anti-LyGCBD BiosciencesCat# 562081; RRID-AB_2722581BV630-conjugated anti-LyGCBD BiosciencesCat# 10510; RRID-AB_2722581BV630-conjugated anti-LyGCBD BiosciencesCat# 10510; RRID-AB_2722581BV630-conjugated anti-LyGCBD BiosciencesCat# 10510; RRID-AB_2727949PerCP-cy5.5-conjugated anti-LyGCBioLegendCat# 10510; RRID-AB_21713PerCP-cy5.5-conjugated anti-LyGCThermoFischerCat# 45-6773-82; RRID-AB_2914351FUK-168)ThermoFischerCat# 45-6773-82; RRID-AB_2906259Pe-conjugated anti-Lymphotxin betaThermoFischerCat# 45-4321-80; RRID-AB_2906259Pe-conjugated anti-Lymphotxin betaSigma-AldrichCat# 4361Botras until 40 sodium salt BioChemicPanPeacAppliChemCat# 4361Botras until 40 sodium salt BioChemicSigma-AldrichCat# 4362DAT 0.5M, PH 8.0Sigma-Aldrich	Rat anti-E-Cadherin (DECMA-1)	Abcam	Cat# Ab11512; RRID:AB_298118
Wheat Germ Agglutinin ThermoFisher Cat# (CM790162, RRID-AB_2334867 APC-conjugated anti-CD13 (145-2C11) BioLegend Cat# 100311; RRID-AB_312676 BV650-conjugated anti-CD19 BioLegend Cat# 47-0114-82; RRID-AB_12676 BV650-conjugated anti-CD110 (M170) ThermoFischer Cat# 47-0114-82; RRID-AB_1548652 BV785-conjugated anti-CD110 (M170) BD Biosciences Cat# 563087; RRID-AB_2721775 Pe-C97-conjugated anti-CD110 (M170) BioLegend Cat# 101216; RRID-AB_2721795 BV605-conjugated anti-CD110 (M170) BD Biosciences Cat# 562081; RRID-AB_2721795 BV605-conjugated anti-Ly6G BD Biosciences Cat# 562081; RRID-AB_2721795 BV605-conjugated anti-Ly6G BioLegend Cat# 127616; RRID-AB_1272171 FITC-conjugated anti-Ly6G BioLegend Cat# 100510; RRID-AB_1877271 FITC-conjugated anti-Ly6G BioLegend Cat# 45-6773-82; RRID-AB_914351 FITC-Chy5.5-conjugated anti-Ly6G BioLegend Cat# 45-6773-82; RRID-AB_914351 FITC-Chy5.5-conjugated anti-Ly6G BioLegend Cat# 45-4321-80; RRID-AB_914351 FITC-Chy5.5-conjugated anti-Ly6G ThermoFischer Cat# 45-4321-80; RRID-AB_91451 FUC-Chy5.5-conjugated	Rabbit anti-Lysozyme1 (polyclonal)	ThermoFischer	Cat# PA5-16668; RRID:AB_10984852
APC-conjugated anti-CD3 (145-2C11)BioLegendCat# 100311; RRID-RB_312876BV680-conjugated anti-CD10 (M418)ThermoFischerCat# 302238; RRID-AB_562097APC-eF780-conjugated anti-CD110 (M418)ThermoFischerCat# 47-0114-82; RRID-AB_548652BY785-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID-AB_312799BV785-conjugated anti-CD11b (M1/70)BioLegendCat# 101216; RRID-AB_312799BV475-conjugated anti-LSQE FBD BiosciencesCat# 562081; RRID-AB_2721775BV605-conjugated anti-LSQEBD BiosciencesCat# 562081; RRID-AB_2721794BV7CP-cy5.5-conjugated anti-Ly6CBD BiosciencesCat# 562081; RRID-AB_2737494PerCP-cy5.5-conjugated anti-Ly6CBioLegendCat# 127616; RRID-AB_137271FTC-conjugated anti-Ly6CBioLegendCat# 127616; RRID-AB_137271FTC-conjugated anti-Ly6CBioLegendCat# 45573-82; RRID-AB_912513PerCP-cy5.5-conjugated anti-Ly6CThermoFischerCat# 45-5773-82; RRID-AB_914351FTC-conjugated anti-Ly6DThermoFischerCat# 45-571-82, RRID-AB_914351PerCP-cy5.5-conjugated anti-Ly70Sigma-AldrichCat# 45518PerCP-cy5.5-conjugated anti-Ly70Sigma-AldrichCat# 45261Perconjugated anti-Ly70Sigma-AldrichCat# A9518Cat# A050Sigma-AldrichCat# A9518Cat# A050Sigma-AldrichCat# A9518Cat# A014Sigma-AldrichCat# A9518Cat# A014Sigma-AldrichCat# A9516Cat# A026Sigma-AldrichCat# A0262Cat# A026Sigma-AldrichCa	Wheat Germ Agglutinin	ThermoFisher	Cat# ICN790162, RRID:AB_2334867
BioLegendBioLegendCat# 302238; RRID:AB_2562097APC-e780-conjugated anti-CD11c (N418)ThermoFischerCat# 47-0114-82; RRID:AB_1548652FTC-conjugated anti-MHC-II (M5/ThermoFischerCat# 11-5321-82; RRID:AB_46532114.15.2)BD BiosciencesCat# 563087; RRID:AB_2727175BV785-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID:AB_272281BV241-conjugated anti-CD11b (M1/70)BioLegendCat# 563087; RRID:AB_272281BV605-conjugated anti-Ly6CBD BiosciencesCat# 563011; RRID:AB_2737949PerCP-cy5.5-conjugated anti-Ly6CBioLegendCat# 107616; RRID:AB_17271PerCP-cy5.5-conjugated anti-Ly6CBioLegendCat# 405017; RRID:AB_17271PerCP-cy5.5-conjugated anti-Ly6CBioLegendCat# 405017; RRID:AB_17271PerCP-cy5.5-conjugated anti-Ly6D4 (RM4-5)BioLegendCat# 45-4321-80; RRID:AB_912513PerCP-cy5.5-conjugated anti-loxppThermoFischerCat# 45-4321-80; RRID:AB_906259Q622a, (BE3a)ThermoFischerCat# 45-4321-80; RRID:AB_906259PerCP-cy5.5-conjugated anti-loxppThermoFischerCat# 45-4321-80; RRID:AB_906259Chemicals, peptides, and recombinant proteinsThermoFischerCat# 45-4321-80; RRID:AB_906259Perconjugated anti-Lymphotoxin betaSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicS	APC-conjugated anti-CD3 (145-2C11)	BioLegend	Cat# 100311; RRID:AB_312676
APC-eF780-conjugated anti-CD11c (N418)ThermoFischerCatif 47-0114-82; RRID:AB_1548652FTC-conjugated anti-MMC-II (M5/ThermoFischerCatif 11-5321-82; RRID:AB_465232BV785-conjugated anti-CD11b (M1/70)BioLegendCatif 101216; RRID:AB_2721775Pe-Cy7-conjugated anti-US10g (M290)BD BiosciencesCatif 562681; RRID:AB_272179BV805-conjugated anti-L9GCBD BiosciencesCatif 562681; RRID:AB_273949PerCP-cy5.5-conjugated anti-L9GCBD BiosciencesCatif 10216; RRID:AB_2739494PerCP-cy5.5-conjugated anti-L9GCBioLegendCatif 100510; RRID:AB_172721FTC-conjugated anti-L9GBioLegendCatif 45-6737-82; RRID:AB_132713PerCP-Cy5.5-conjugated anti-L9GBioLegendCatif 45-6773-82; RRID:AB_906259PerCP-Cy5.5-conjugated anti-lostypeThermoFischerCatif 45-671-82; RRID:AB_906259PerCP-Cy5.5-conjugated anti-lostypeThermoFischerCatif 45-671-82; RRID:AB_906259PerCP-Cy5.5-conjugated anti-lostypeThermoFischerCatif 45-671-82; RRID:AB_906259PerCP-Cy5.5-conjugated anti-lostypeSigma-AldrichCatif 450518PerCP-Cy5.5-conjugated anti-lost	BV650-conjugated anti-CD19	BioLegend	Cat# 302238; RRID:AB_2562097
FITC-conjugated anti-MHC-II (M5/ ThermoFischer Cat# 11-5321-62; RRID:AB_465232 114.15.2) BD Biosciences Cat# 563087; RRID:AB_2721775 Pe-Cy7-conjugated anti-CD103 (M290) BD Biosciences Cat# 563087; RRID:AB_2721775 Pe-Cy7-conjugated anti-CD11b (M1/70) BioLegend Cat# 101216; RRID:AB_2722581 BV605-conjugated anti-Ly6C BD Biosciences Cat# 26601; RRID:AB_2727949 PerCP-cy5.5-conjugated anti-Ly6G BioLegend Cat# 107616; RRID:AB_272771 FITC-conjugated anti-Ly6G BioLegend Cat# 107616; RRID:AB_917271 FITC-conjugated anti-Ly6G BioLegend Cat# 45-5773-82; RRID:AB_914351 FITC-conjugated anti-Ly6G ThermoFischer Cat# 45-4321-80; RRID:AB_906259 IgG2a,k (eBR2a) ThermoFischer Cat# 45-4321-80; RRID:AB_906259 Pe-conjugated anti-Lymphotoxin beta ThermoFischer Cat# 45-4321-80; RRID:AB_906259 IgG2a,k (eBR2a) ThermoFischer Cat# 45-4321-80; RRID:AB_906259 Pe-Conjugated anti-Lymphotoxin beta ThermoFischer Cat# 45-4321-80; RRID:AB_906259 IgG2a,k (eBR2a) Sigma-Aldrich Cat# A5-4321-80; RRID:AB_906259 IgG2a,k (eBR2a) Sigma-Aldrich	APC-eF780-conjugated anti-CD11c (N418)	ThermoFischer	Cat# 47-0114-82; RRID:AB_1548652
BV785-conjugated anti-CD103 (M290)BD BiosciencesCat# 563087; RRID:AB_2721775Pe-Cy7-conjugated anti-CD11b (M170)BiolegendCat# 101216; RRID:AB_312799BV421-conjugated anti-Ly6CBD BiosciencesCat# 562681; RRID:AB_2737949PerCP-cy5.5-conjugated anti-Ly6GBD BiosciencesCat# 100510; RRID:AB_2737949PerCP-cy5.5-conjugated anti-Ly6GBiolegendCat# 100510; RRID:AB_2737949PerCP-cy5.5-conjugated anti-Ly6GBiolegendCat# 100510; RRID:AB_312713PerCP-Cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-571-82; RRID:AB_906259PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-571-82; RRID:AB_2016713PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-571-82; RRID:AB_2016713PerCP-Cy5.5-conjugated anti-IsotypeSigma-AldrichCat# 49518PerCP-Cy5.5-conjugated anti-IsotypeSigma-AldrichCat# 49518PerCP-Cy5.5-conjugated anti-IsotypeSigma-AldrichCat# 49518PerCP-Cy5.5-conjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518Perconjugated anti-Lymphotoxin betaSigma-AldrichCat# 40510	FITC-conjugated anti-MHC-II (M5/ 114.15.2)	ThermoFischer	Cat# 11-5321-82; RRID:AB_465232
Pe-Cy7-conjugated anti-CD11b (M1/70)BioLegendCat# 101216; RRID:AB_312799BV421-conjugated anti-Siglec FBD BiosciencesCat# 562681; RRID:AB_2722581BV605-conjugated anti-Ly6GBioLegendCat# 263011; RRID:AB_1277211FITC-conjugated anti-Ly6G (M44-5)BioLegendCat# 1001010; RRID:AB_312713PerCP-Cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-5773-82; RRID:AB_906259IgG2a,k (eBR2a)ThermoFischerCat# 45-671-82, RRID:AB_906259Pe-conjugated anti-Lymphotoxin betaThermoFischerCat# 45-671-82, RRID:AB_906259IgG2a,k (eBR2a)Sigma-AldrichCat# 49518Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# 49518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# M3262VancomycinSigma-AldrichCat# 40262VancomycinSigma-AldrichCat# 10236276001Amphotericin BSigma-AldrichCat# 250-311Amphotericin BSigma-AldrichCat# 250-311DAPISigma-AldrichCat# 10236276001Amphotericin BSigma-AldrichCat# 10236276001DAPIPreprotechCat# 315-17Amphotericin BSigma-AldrichCat# 315-17DAPISigma-AldrichCat# 315-17DAPISigma-AldrichCat# 10236276001Amphotericin BSigma-AldrichCat# 315-17DAPISigma-AldrichCat# 315-17DAPISigma-AldrichCat# 315-17 <td>BV785-conjugated anti-CD103 (M290)</td> <td>BD Biosciences</td> <td>Cat# 563087; RRID:AB_2721775</td>	BV785-conjugated anti-CD103 (M290)	BD Biosciences	Cat# 563087; RRID:AB_2721775
BV421-conjugated anti-Siglec FBD BiosciencesCat# 562681; RRID:AB_2722581BV605-conjugated anti-Ly6CBD BiosciencesCat# 563011; RID:AB_2737949PerCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 100510; RRID:AB_1877211FITC-conjugated anti-Foxp3BioLegendCat# 45-5773-82; RRID:AB_914351(FJK-16s)ThermoFischerCat# 45-5773-82; RRID:AB_914351PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-4321-80; RRID:AB_906259PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 12-5671-82, RRID:AB_906259PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 12-5671-82, RRID:AB_2016713PerCP-Cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-4321-80; RRID:AB_2016713PerCP-Cy5.5-conjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518PerCP-Cy5.5-conjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518Perconjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518Perconjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518Dextran sulfate 40 sodium salt BioChemicPanReaCAppliChemCat# 49518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# 49518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# 49518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# 40262StreptomycinSigma-AldrichCat# 40262StreptomycinSigma-AldrichCat# 40262DaPISigma-AldrichCat# 40262Recombinant Murine FIt3-LigandPreprotechCat#	Pe-Cy7-conjugated anti-CD11b (M1/70)	BioLegend	Cat# 101216; RRID:AB_312799
BV605-conjugated anti-Ly6CBD BiosciencesCat# 563011; RRID:AB_7273949PerCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 127616; RRID:AB_1877271FITC-conjugated anti-CD4 (RM4-5)BioLegendCat# 4100510; RRID:AB_312713PerCP-cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351(FJK-16s)ThermoFischerCat# 45-5773-82; RRID:AB_916259PerCP-cy5.5-conjugated anti-IsotypeThermoFischerCat# 45-4321-80; RRID:AB_906259PerCP-cy5.5-conjugated anti-Lymphotoxin betaThermoFischerCat# 412-5671-82, RRID:AB_906259PerCP-cy5.5-conjugated anti-Lymphotoxin betaThermoFischerCat# 425-671-82, RRID:AB_2016713Percorjugated anti-Lymphotoxin betaSigma-AldrichCat# 49518Chemicals, peptides, and recombinant proteinsCat# 40501Cat# 49518PertoriousSigma-AldrichCat# 409620BotrogenSigma-AldrichCat# 408620StreptomycinSigma-AldrichCat# 408620StreptomycinSigma-AldrichCat# 403761Anphotericin BSigma-AldrichCat# 4023676001Angendericin BSigma-AldrichCat# 250-31LDAPICat# 250-31LCat# 250-31LRecombinant Murine FId-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 240-31-37Doxycocline hyclateSigma-AldrichCat# 17378Doxycocline hyclateSigma-AldrichCat# 17378Doxycocline hyclateSigma-AldrichCat# 17378Doxycocline hyclateSigma-AldrichCat# 123105	BV421-conjugated anti-Siglec F	BD Biosciences	Cat# 562681; RRID:AB_2722581
PerCP-cy5.5-conjugated anti-Ly6GBioLegendCat# 127616; RRID:AB_1877271FITC-conjugated anti-CD4 (RM4-5)BioLegendCat# 100510; RRID:AB_312713PerCP-Cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351PerCP-Cy5.5-conjugated anti-lsotypeThermoFischerCat# 45-4321-80; RRID:AB_906259IgG2a,k (eBR2a)ThermoFischerCat# 12-5671-82; RRID:AB_906259Pe-conjugated anti-Lymphotoxin betaThermoFischerCat# 12-5671-82; RRID:AB_906259Receptor (eBio3C8)Sigma-AldrichCat# 45-4321-80; RRID:AB_906259Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# 45-671-82; RRID:AB_906259AmpicillinSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# A9518Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# 409501StreptomycinSigma-AldrichCat# 409502VancomycinSigma-AldrichCat# 203276001Amphotericin BSigma-AldrichCat# 203276001DAPISigma-AldrichCat# 315-03Recombinant Murine FIt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 10238276001NomethacinSigma-AldrichCat# 10238276001Doxycycline hyckateSigma-AldrichCat# 315-03Doxycycline hyckateSigma-AldrichCat# 315-03Doxycycline hyckateSigma-AldrichCat# 315-03Doxycycline hyckateSigma-AldrichCat# 10238276001Doxycycline hyckateSigma-Aldrich <td>BV605-conjugated anti-Ly6C</td> <td>BD Biosciences</td> <td>Cat# 563011; RRID:AB_2737949</td>	BV605-conjugated anti-Ly6C	BD Biosciences	Cat# 563011; RRID:AB_2737949
FITC-conjugated anti-CD4 (RM4-5)BioLegendCat# 100510; RRID:AB_312713PerCP-Cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351(FJK-163)ThermoFischerCat# 45-4321-80; RRID:AB_906259PerCP-Cy5.5-conjugated anti-Lymphotoxin betaThermoFischerCat# 45-4321-80; RRID:AB_906259Pe-conjugated anti-Lymphotoxin betaThermoFischerCat# 12-5671-82, RRID:AB_2016713Receptor (eBio3C8)Sigma-AldrichCat# A9518Devtran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A9261EDTA 0.5M, pH 8.0InvitrogenCat# M3761StreptomycinSigma-AldrichCat# M3761EDTA 0.5M, pH 8.0Sigma-AldrichCat# A9262Maphotericin BSigma-AldrichCat# M3261DAPISigma-AldrichCat# A0262Marchin BSigma-AldrichCat# A0262Marchin BSigma-AldrichCat# A0262DAPISigma-AldrichCat# A0262Recombinant Murine FR3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 315-17Doxycycline hyclateSigma-AldrichCat# 315-03Christer SubstrationSigma-AldrichCat# 315-03Murine PDGF-AAPreprotechCat# 315-03Doxycycline hyclateSigma-AldrichCat# 315-03Christer SubstrationSigma-AldrichCat# 315-03Murine PDGF-AASigma-AldrichCat# 31	PerCP-cy5.5-conjugated anti-Ly6G	BioLegend	Cat# 127616; RRID:AB_1877271
PerCP-Cy5.5-conjugated anti-Foxp3ThermoFischerCat# 45-5773-82; RRID:AB_914351PerCP-Cy5.5-conjugated anti-Isotype (gG2a,k (eBR2a)ThermoFischerCat# 45-4321-80; RRID:AB_906259PerCP-Cy5.5-conjugated anti-Lymphotoxin beta Receptor (eBio3C8)ThermoFischerCat# 12-5671-82, RRID:AB_2016713Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# A9518Chemicals, peptides, and recombinant proteinsInvitrogenCat# A9261Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# A9261Chemicals, peptides, and recombinant proteinsInvitrogenCat# A9261Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# A9261Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# A9261Chemicals, peptides, and recombinant gigma-AldrichCat# A9518Sigma-AldrichDextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A0262Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A0262Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A0262Dextran sulfate 40 sodium salt BioChemicSigma-AldrichCat# A0262Chemicals assoSigma-AldrichCat# 4088Sigma-AldrichVancomycinSigma-AldrichCat# 44888Sigma-AldrichApplotericin BSigma-AldrichCat# 250-31LSigma-AldrichRecombinant Murine FH3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17Sigma-AldrichIndomethacinSigma-AldrichCat# 17	FITC-conjugated anti-CD4 (RM4-5)	BioLegend	Cat# 100510; RRID:AB_312713
PerCP-Cy5.5-conjugated anti-Isotype (gG2a,k (eBR2a)ThermoFischerCat# 45-4321-80; RRID:AB_906259Pe-conjugated anti-Lymphotoxin beta Receptor (eBio3C8)ThermoFischerCat# 12-5671-82, RRID:AB_2016713Chemicals, peptides, and recombinant proteinsSigma-AldrichCat# A9518Chemicals, peptides, and recombinant proteinsCat# A9518Dextran sulfate 40 sodium salt BioChemicPerconjugated anti-Lymphotoxin betaSigma-AldrichCat# A9261EDTA 0.5M, pH 8.0InvitrogenCat# AM9262EDTA 0.5M, pH 8.0InvitrogenCat# AM9262MetronidazoleSigma-AldrichCat# X6501StreptomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# 44888DAPISigma-AldrichCat# 250-31LRecombinant Murine Flt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 17378Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 109991Critical commercial assaysFixation-permeabilization bufferEdiscienceFixation-permeabilization bufferReloxeinceCat# 00-5521-00	PerCP-Cy5.5-conjugated anti-Foxp3 (FJK-16s)	ThermoFischer	Cat# 45-5773-82; RRID:AB_914351
Pe-conjugated anti-Lymphotoxin beta Receptor (eBio3C8)ThermoFischerCat# 12-5671-82, RRID:AB_2016713Chemicals, peptides, and recombinant proteinsAmpicillinSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# A3261EDTA 0.5M, pH 8.0InvitrogenCat# M9262MetronidazoleSigma-AldrichCat# M9761StreptomycinSigma-AldrichCat# V1150VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# 4888DAPISigma-AldrichCat# 10236276001Recombinant Murine FIt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-03Murine PDGF-AASigma-AldrichCat# 315-17IndomethacinSigma-AldrichCat# 10236276001Doxycycline hyclateSigma-AldrichCat# 315-03Crittcal commercial assaysSigma-AldrichCat# 315-03Fixable Blue Dead Cell Stain KitInvitrogenCat# 102305Fixation-permeabilization buffereBioscienceCat# 250-00	PerCP-Cy5.5-conjugated anti-Isotype IgG2a,k (eBR2a)	ThermoFischer	Cat# 45-4321-80; RRID:AB_906259
Chemicals, peptides, and recombinant proteinsAmpicillinSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# A3261EDTA 0.5M, pH 8.0InvitrogenCat# AM9262MetronidazoleSigma-AldrichCat# M3761StreptomycinSigma-AldrichCat# S6501VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# 44888DAPISigma-AldrichCat# 250-31LRecombinant Murine Fit3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-03IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 290-911Dritcal commercial assaysSigma-AldrichCat# 213105Fixable Blue Dead Cell Stain KitInvitrogenCat# 00-5521-00	Pe-conjugated anti-Lymphotoxin beta Receptor (eBio3C8)	ThermoFischer	Cat# 12-5671-82, RRID:AB_2016713
AmpicillinSigma-AldrichCat# A9518Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# A3261Dextran sulfate 40 sodium salt BioChemicInvitrogenCat# AM9262EDTA 0.5M, pH 8.0Sigma-AldrichCat# M3761MetronidazoleSigma-AldrichCat# S6501StreptomycinSigma-AldrichCat# V1150VancomycinSigma-AldrichCat# A4888DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-03Doxycycline hyclateSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# 123105Fixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Chemicals, peptides, and recombinant proteins		
Dextran sulfate 40 sodium salt BioChemicPanReacAppliChemCat# A3261EDTA 0.5M, pH 8.0InvitrogenCat# AM9262MetronidazoleSigma-AldrichCat# M3761StreptomycinSigma-AldrichCat# S6501VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# 44888DAPISigma-AldrichCat# 250-31LRecombinant Murine Flt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 1028276001Dxycycline hyclateSigma-AldrichCat# 315-03Dxycycline hyclateSigma-AldrichCat# 315-03Fixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Ampicillin	Sigma-Aldrich	Cat# A9518
EDTA 0.5M, pH 8.0InvitrogenCat# AM9262MetronidazoleSigma-AldrichCat# M3761StreptomycinSigma-AldrichCat# S6501VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# A4888DAPISigma-AldrichCat# 250-31LRecombinant Murine Flt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-03IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Fixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Dextran sulfate 40 sodium salt BioChemic	PanReacAppliChem	Cat# A3261
MetronidazoleSigma-AldrichCat# M3761StreptomycinSigma-AldrichCat# S6501VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# A4888DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 10381Doxycycline hyclateSigma-AldrichCat# 109891Frkable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	EDTA 0.5M, pH 8.0	Invitrogen	Cat# AM9262
StreptomycinSigma-AldrichCat# S6501VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# A4888DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 107378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysFixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Metronidazole	Sigma-Aldrich	Cat# M3761
VancomycinSigma-AldrichCat# V1150Amphotericin BSigma-AldrichCat# A4888DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysFrizable Blue Dead Cell Stain KitInvitrogenCat# 23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Streptomycin	Sigma-Aldrich	Cat# S6501
Amphotericin BSigma-AldrichCat# A4888DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysFixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Vancomycin	Sigma-Aldrich	Cat# V1150
DAPISigma-AldrichCat# 10236276001Recombinant Murine Flt3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysFixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Amphotericin B	Sigma-Aldrich	Cat# A4888
Recombinant Murine Flt3-LigandPreprotechCat# 250-31LRecombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysFrixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	DAPI	Sigma-Aldrich	Cat# 10236276001
Recombinant Murine GM-CSFPreprotechCat# 315-03Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysCriticagenCat# L23105Fixable Blue Dead Cell Stain KitInvitrogenCat# 00-5521-00	Recombinant Murine Flt3-Ligand	Preprotech	Cat# 250-31L
Murine PDGF-AAPreprotechCat# 315-17IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysCat# L23105Fixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Recombinant Murine GM-CSF	Preprotech	Cat# 315-03
IndomethacinSigma-AldrichCat# 17378Doxycycline hyclateSigma-AldrichCat# D9891Critical commercial assaysCritical commercial assaysFixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Murine PDGF-AA	Preprotech	Cat# 315-17
Doxycycline hyclate Sigma-Aldrich Cat# D9891 Critical commercial assays Critical commercial assays Fixable Blue Dead Cell Stain Kit Invitrogen Cat# L23105 Fixation-permeabilization buffer eBioscience Cat# 00-5521-00	Indomethacin	Sigma-Aldrich	Cat# 17378
Critical commercial assays Fixable Blue Dead Cell Stain Kit Invitrogen Cat# L23105 Fixation-permeabilization buffer eBioscience Cat# 00-5521-00	Doxycycline hyclate	Sigma-Aldrich	Cat# D9891
Fixable Blue Dead Cell Stain KitInvitrogenCat# L23105Fixation-permeabilization buffereBioscienceCat# 00-5521-00	Critical commercial assays		
Fixation-permeabilization buffer eBioscience Cat# 00-5521-00	Fixable Blue Dead Cell Stain Kit	Invitrogen	Cat# L23105
	Fixation-permeabilization buffer	eBioscience	Cat# 00-5521-00



Cell Stem Cell 29, 856-868.e1-e5, May 5, 2022 e1

CellPress OPEN ACCESS

Cell Stem Cell Article

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Aldefluor Kit	StemCell Technologies	Cat# 01700
Click-iT™ EdU Cell Proliferation Kit for	ThermoFischer	Cat# C10340
Imaging, AF [™] 647 dye		
Single Cell RNA Purification Kit	Norgen	Cat# 51800
Qubit RNA HS kit	ThermoFischer	Cat# Q32852
Qubit dsDNA HS kit	ThermoFischer	Cat# Q32854
Agilent RNA 6000 Pico Kit	Agilent	Cat# 5067-1513
SuperScript IV Reverse Transcriptase	Invitrogen	Cat# 18090010
SsoAdvanced Universal SYBR Green Supermix	BioRad	Cat# 1725275
SMARTer® Stranded Total RNA-SeqKit v2- Pico Input	Takara Bio	Cat# 634412
NextSeq 500/550 High Output Kit v2.5 (75 Cycles)	Illumina	Cat# 20024906
Deposited data		
Raw and processed RNAseq data of	This paper	GEO: GSE200362
intestinal YFP ⁺ and YFP ⁻ stromal cells		
Raw and processed RNAseq data of intestinal YFP ⁺ and YFP ⁻ stromal cells after indomethacin	This paper	GEO: GSE200364
Raw and processed RNAseq data of intestinal YFP ⁺ PDGFR α^+ and YFP ⁺ PDGFR α^- stromal cells	This paper	GEO: GSE200363
Experimental models: Organisms/strains		
Ltbr-Cre-IRES-eGFP	This paper	N/A
Ltbr-tTA-IRES-DTR	This paper	N/A
Pdgfra ^{floxed} (Pdgfra-tm8Sor/EiJ)	The Jackson Laboratory	JAX stock #006492
LC1 (Tg(tetO-cre)LC1Bjd)	Schonig et al., 2002	MGI:2448952
Rosa26 ^{EYFP} (B6.129X1-Gt(ROSA) 26Sor ^{tm1(EYFP)Cos} /J)	Srinivas et al., 2001	JAX stock #006148
Lgr5-eGFP-IRES-CreERT2 (B6.129P2- Lgr5 ^{tm1(cre/ERT2)Cle} /J)	The Jackson Laboratory	JAX stock #008875
VE-Cadherin-Cre (B6.FVB-Tg(Cdh5-cre) 7Mlia/J)	The Jackson Laboratory	JAX stock #006137
Oligonucleotides		
gRT-PCR mouse Axin2 primer assay	Biorad	gMmuCED0044828
gRT-PCR mouse Muc2 primer assay	Biorad	qMmuCID0019583
gRT-PCR mouse Tff3 primer assay	Biorad	qMmuCID0008757
qRT-PCR mouse Tip2 primer assay	Biorad	qMmuCEP0054545
gRT-PCR mouse Sis primer assay	Biorad	qMmuCID0015908
gRT-PCR mouse II18 primer assay	Biorad	qMmuCID0005876
qRT-PCR mouse II1b primer assay	Biorad	qMmuCID0005641
gRT-PCR mouse Pdgfa primer assay	Biorad	qMmuCID0022342
qRT-PCR mouse Cdk1 primer assay	Biorad	qMmuCID0015611
qRT-PCR mouse Mki67 primer assay	Biorad	qMmuCED0047197
Additional primers are found in Table S1	N/A	N/A
Software and algorithms		
R project for Statistical Computing	R foundation	RRID: SCR_001905
DESeq2	Love et al., 2014	Bioconductor DESeg2
FlowJo-v10	FlowJo, LLC	RRID:SCR_008520
Prism 6	GraphPad	RRID: SCR_002798



Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
ZEN Image Acquisition Software	Zeiss Microscope	RRID: SCR_013672
Fiji	Image J	RRID: SCR_002285
Adobe Photoshop CC	Adobe Systems	RRID: SCR_014199
Other		
RNAscope probe: Mm- <i>Lgr5</i>	ACDBio	312171

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lucie Peduto (lucie.peduto@pasteur.fr).

Materials availability

Material generated in this study is available from the lead contact upon request, with a completed Materials Transfer Agreement.

Data and code availability

- The raw data of bulk RNA-seq generated by this study have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GEO: GSE200365. Accession numbers of each dataset are listed in the key resources table.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

All mice were kept in specific pathogen-free conditions, and mouse experiments were approved by the committee on animal experimentation of the Institut Pasteur and by the French Ministry of Agriculture. Co-housed non-transgenic littermates were used as controls in all experiments; experimental groups were both age and sex matched. All mice were C57BL/6 background. We generated BAC-transgenic LTBR-cre-ires-egfp mice (LTBR^{GFP}), by inserting the coding sequence for cre-ires-egfp, including a poly(A) sequence after egfp, into exon 1 of Ltbr in place of the endogenous ATG translation start codon, on a 200-kb BAC (Invitrogen) carrying 80 kb of sequence upstream of the Ltbr translation start site. The transgene insertion was done by homologous recombination as described (Sparwasser et al., 2004). We generated BAC-transgenic Ltbr-tTA-ires-Dtr mice (LTBR^{tTA}), by inserting the coding sequence for tTA-ires-Dtr (human), including a poly(A) sequence after Dtr, into exon 1 of Ltbr in place of the endogenous ATG translation start codon, on a 200-kb BAC as described above. We carried out inducible fate mapping experiments in triple-transgenic LTBR^{YFP} mice obtained by crossing LTBR^{ITA} mice with tet-inducible LC1 mice (Schonig, 2002), and with Rosa26^{floxSTOP-YFP} mice (Srinivas et al., 2001). In both BAC-transgenic models, GFP and YFP expression was consistent with reported expression of LTBR. Inducible conditional ablation of PDGFRa in the LTBR lineage was achieved by crossing LTBR^{tTA} mice to tet-regulated Cre (LC1) mice and PDGFRα^{fl/fl} mice (Jackson Laboratories) to obtain LTBR^{ΔPDGFRa} mice. In some experiments, LTBR^{ΔPDGFRa} mice were further crossed to Rosa26^{floxSTOP-YFP} mice (LTBR^{△PDGFRa/YFP} mice). Lgr5-EGFP-IRES-creERT2 mice (Barker et al., 2007) were purchased from The Jackson Laboratories. VE-cadherin-Cre mice specifically express Cre by vascular endothelial-cadherin (Cdh5) (The Jackson Laboratories) were crossed to Rosa26^{floxSTOP-YFP} mice for lineage tracing studies.

Mice treatment

To stop gene labeling or gene excision in the tTA mice models, doxycycline (Sigma-Aldrich) at 1 mg/ml was added in drinking water containing 5% sucrose, during the indicated periods of time. To assess epithelial proliferation, mice were injected i.p. with 80µl of EdU 10mM and analyzed 2 hours after injection. To induce intestinal ulcers, mice were injected intra-peritoneally with indomethacin (10mg/kg). To visualize ulcers, mice were injected with Evan's Blue 1% intra-venously 30 min before killing. Intestines were opened, pinned down and intestinal ulcers were counted and their area was measured using Fiji based on evan's blue diffusion. To induce intestinal inflammation, mice were treated with Dextran Sodium Sulfate (DSS) 2,5% in drinking water for one week. To deplete the microbiota, mice were treated from late gestation with 2.5 mg/ml streptomycin, 1 mg/ml ampicillin, 0.5 mg/ml vancomycin, metro-nidazole 0.5 mg/ml and amphotericin b 0.1mg/mL in the drinking water. The antibiotic-containing drinking water was changed twice a week.



METHOD DETAILS

Tissue preparation and immunostaining

Intestines were washed, opened and fixed overnight at 4°C in solution of 4% paraformaldehyde (PFA). For immunofluorescence, samples were washed for 24h in PBS, incubated for 2–4h in a solution of 30% sucrose in PBS, embedded in OCT, and frozen in a bath of isopentane cooled with liquid nitrogen. Frozen blocs were cut at 8um thickness and sections collected onto Superfrost Plus slides. Sections were processed for immunofluorescence staining: after 1h blocking with 10% bovine serum in PBS containing 0,1% Triton at room temperature, slides were incubated with primary antibodies at the appropriate concentration in PBS containing 1% bovine serum and 0,1% Triton (PBS-TS) overnight at 4°C, washed three times for 5 min with PBS-TS, incubated for 1h at room temperature with secondary antibodies or streptavidin at the appropriate concentration, washed once, incubated with DAPI (1ug/mL) for 5 min, washed three times for 5 min and mounted with Fluoromount-G (Southern Biotechnology Associates). For pathological assessment, intestines were fixed in PFA, incubated in ethanol and embedded in paraffin. Paraffin blocs were cut a 4µm for hematoxylin and eosin coloration. Lgr5 expression was detected with an RNAscope ISH assay (Advanced Cell Diagnostics - ACDBio), following the manufacturer's instructions. We examined slides with an AxioImager M1 fluorescence microscope (Zeiss) equipped with a CCD camera and processed images with AxioVision Zen software (Zeiss) or ImageJ software. The graphical abstract was created using Biorender.com.

Cell isolation and flow cytometry

To isolate cells from the small intestine lamina propria, Peyer's patches were removed, intestine opened longitudinally, cut into pieces and processed as we previously described (Stzepourginski et al., 2015). To isolate cells from the LN, LN were incubated for 30min in DMEM containing Liberase DL (1 Wunit/mL; Roche) and DNAse I (1 U/ml; ThermoFisher). Cells were filtered through a 100-um mesh in DMEM 10% BS, washed, filtered through a 40um filter in PBS 2% BS, and processed for FACS staining (Stzepourginski et al., 2015). Cells were incubated for 1 min with DAPI (Sigma) before analysis to exclude dead cells. When indicated, the fusion protein LT β R-Ig or IgG control proteins (Rennert et al., 1998) were pre-incubated with anti-LT β R antibodies. For intracellular FACS staining, we incubated cells with LIVE/DEADTM Fixable Blue Dead Cell Stain Kit following the manufacturer instruction, and processed for intracellular staining using FoxP3/Transcription Factor Staining Buffer Kit. Cells were fixed and permeabilized according to the manufacturer's instructions. Retinoic Acid production by dendritic cells was assessed using the Aldefluor kit according to manufacturer's instructions. Cell doublets were excluded during analysis. Cells were analyzed with Fortessa (BD Biosciences) and Flowjo software (Tristar) and isolated with FacsARIA III (BD Biosciences). The immune populations were gated as follow: CD19⁺ cells, usere gated on CD45⁺CD19⁻CD3⁻IL⁻7R⁺ cells, CD103⁺CD11b⁻ DCs and CX₃CR1⁺ mononuclear phagocytes were gated on CD45⁺CD19⁻CD3⁻CD11c^{-/low}MHC-II^{-/low}CD11b⁺ cells.

RNA Isolation and qRT-PCR

We FACS sorted cells, or collected epithelial cells directly into vials containing lysis buffer complemented with 1% β-mercaptoethanol. We isolated total RNA using the Single Cell RNA Purification Kit (Norgen) according to the manufacturer's instructions. We assessed the quality of total RNA using the 2100 Bioanalyzer system (Agilent Technologies) and the quantity using Qbit RNA HS kit (ThermoFischer). Total RNA was transcribed into cDNAs using SuperScript IV reverse transcriptase (Invitrogen). We performed qRT-PCR using RT²-qPCR primer sets (Bio-Rad Laboratories) and SYBR-Green master mix (Bio-Rad Laboratories), on a PTC-200 thermocycler equipped with a Chromo4 detector (Bio-Rad Laboratories), and analyzed data using Opticon Monitor software (Bio-Rad Laboratories). Ct values were normalized to the mean of Ct values obtained for the housekeeping genes *Hsp90ab1*, *Hprt*, and *Gapdh*.

RNA sequencing

Librairies were prepared from total mRNA using the SMARTer® Stranded Total RNA-Seq Kit v2-Pico Input Mammalian (Takara Bio) according to the manufacturer's instruction. Library quality and quantity were assessed using the 2100 Bioanalyzer system (Agilent Technologies) and the Qbit dsDNA HS kit (ThermoFischer). Sequencing was performed using Illumina NextSeq 500/550 High Output kit v2.5. The RNA-seq analysis was performed with Sequana 0.11.0 (https://github.com/sequana/sequana_maseq) built on top of Snakemake 6.1.1 (Koster and Rahmann, 2012). Briefly, reads were trimmed from adapters using cutadapt 3.4 then mapped to the genome assembly GRCm38 from Ensembl using STAR 2.7.3a. FeatureCounts 2.0.1 was used to produce the count matrix, assigning reads to features using corresponding annotation GRCm38_92 from Ensembl with strand-specificity information. Quality control statistics were summarized using MultiQC 1.10.1 (Ewels et al., 2016). Clustering of transcriptomic profiles were assessed using a Principal Component Analysis (PCA). Differential expression testing was conducted using DESeq2 library 1.24.0 (Love et al., 2014) and SARTOOLS scripts (Varet et al., 2016). The normalization and dispersion estimation were performed with DESeq2 using the default parameters; statistical tests for differential expression were performed applying the independent filtering algorithm. A generalized linear model was set in order to test for the differential expression between conditions. Raw p-values were adjusted for multiple testing according to the Benjamini and Hochberg procedure and genes with an adjusted p-value lower than 0.05 were considered differentially expressed. Gene set enrichment analysis was performed using the fisher statistical test for the over-representation of up-regulated genes.





Cell culture

FACS sorted intestinal PDGFR α^+ Pdpn⁺ stromal cells were plated in complete RPMI medium for 3 days. *In vitro* differentiation of CD103⁺CD11b⁺ BM-DCs was performed as previously described. Briefly, one million total BM cells were cultured in CM containing GM-CSF (Preprotech, 20ng/mL) and FLT3L (Preprotech, 100ng/mL) with partial change of medium at day 3 and 5. At days 7, cells were collected. For experiments, DCs were co-cultured +/- stromal cells in complete medium lacking GM-CSF and FLT3L for 3 days, and analyzed by FACS. In some experiments, PDGFR α^+ Pdpn⁺ stromal cells were incubated O/N with 20ng/mL of PDGF-AA in medium containing reduced serum.

QUANTIFICATION AND STATISTICAL ANALYSIS

For quantification of immunofluorescence stainings, we examined slides with an AxioImager M1 fluorescence microscope (Zeiss) equipped with a CCD camera. Images were processed with AxioVision Zen software (Zeiss) and quantified using ImageJ software on the indicated number of images per mice. Except for the RNAseq experiments, statistical significance between groups was determined using either Student's t tests, one or two-tailed as appropriate, using GraphPad Prism 6 (GraphPad Software, La Jolla, California). Unless otherwise specified, n represents the number of animals. Values are expressed as means ± standard deviation (SD). A p value < 0.05 was considered statistically significant. For all figures, asterisks denote statistical significance and the associated p values are shown in the legends.